Methods for delivering neuroprotective polypeptides to the central nervous system
Patent Information
- Application Number
- JP2019521018
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-10-20
- Filing Date
- 2017-10-20
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2037-10-20
AI Technical Summary
Existing methods for delivering neuroprotective polypeptides like GLP-1 and exendin-4 across the blood-brain barrier (BBB) are inefficient, leading to short half-lives and inadequate treatment of neurodegenerative diseases due to insufficient delivery to the central nervous system.
A controlled release preparation or device is used to administer neuroprotective polypeptides such as GLP-1 and exendin-4, providing sustained delivery and increased uptake across the BBB, using biodegradable polymers and coating materials to maintain stable plasma levels and enhance CNS delivery.
The controlled release method significantly increases the delivery and uptake of neuroprotective polypeptides to the CNS, effectively treating conditions like Parkinson's disease, traumatic brain injury, and Alzheimer's disease by maintaining therapeutic concentrations over time.
Abstract
Description
[Technology Field]
[0001] Cross-reference with related applications This application claims priority under U.S. Provisional Application No. 62 / 410,748, filed on 20 October 2016, which is incorporated herein by reference in its entirety.
[0002] Government funding The research supporting this invention was conducted by the United States, represented by the Secretary of Health and Human Services. The U.S. government has certain rights to this invention.
[0003] Citation In accordance with 37C.FR§1.52(e)(5), the entire sequence information contained in the electronic file (filename: 1568390_100WO2_Sequence_Listing_ST25.txt, size: 24.4KB, created: September 3, 2017 using PATENT-In 3.5 and Checker 4.4.0) is incorporated herein by reference.
[0004] background field This disclosure relates to compositions containing neuroprotective therapeutic polypeptides, such as glucagon-like peptide-1 (GLP-1), exendin-4, and / or their peptide analogs. In particular, this disclosure relates to a method for maintaining stable levels of neuroprotective therapeutic polypeptides in plasma to treat neurodegenerative conditions, thereby facilitating delivery to the brain by crossing the blood-brain barrier (BBB). [Background technology]
[0005] Background technology Glucagon-like peptide-1 (GLP-1) is a hormone normally secreted by intestinal neuroendocrine cells in response to food, but its use as a new treatment for type 2 diabetes has been suggested (Gutniak et al., 1992; Nauck et al., 1993). GLP-1 increases insulin release by beta cells, and this effect is also observed in long-term type 2 diabetes patients (Nauck et al., 1993). GLP-1 stimulates endogenous insulin secretion, and since this stimulation disappears when blood glucose levels decrease, GLP-1 treatment is superior to insulin therapy (Nauck et al., 1993; Elahi et al., 1994). GLP-1 promotes normal blood glucose levels by increasing insulin release and synthesis, inhibiting glucagon release, and reducing gastric emptying (Nauck et al., 1993; Elahi et al., 1994; Wills et al., 1996; Nathan et al., 1992; De Ore et al., 1997). GLP-1 is a post-translational modification product of proglucagon. The sequences of GLP-1 and its active fragments, GLP-1(7-37) and GLP-1(7-36) amides, are well known in the art (Fehmann et al., 1995). Although GLP-1 has been proposed as a therapeutic agent for the treatment of diabetes, it has a short biological half-life (De Ore et al., 1997), and its biological half-life remains short even after bolus subcutaneous administration (Ritzel et al., 1995). The degradation of GLP-1 (and GLP-1(7-36)amide) is partly due to the enzyme dipeptidyl peptidase (DPP 1V), which cleaves this polypeptide between the amino acids at positions 8 and 9 (alanine and glutamic acid).
[0006] Exendin-4 is a polypeptide produced in the salivary glands of the Gila monster lizard (Goke et al., 1993). The amino acid sequence of exendin-4 is well known in the art (Fehmann et al., 1995). Although exendin-4 is a gene product specific to non-mammals and its expression appears to be limited to the salivary glands (Chen and Drucker, 1997), it has 52% amino acid sequence homology with GLP-1 and interacts with the GLP-1 receptor in mammals (Goke et al., 1993; Thorens et al., 1993). In vitro, exendin-4 has been shown to promote insulin secretion by insulin-producing cells, and its efficacy in inducing insulin release by insulin-producing cells is higher than that of equimolar GLP-1 administration. Furthermore, exendin-4 strongly stimulates insulin release and lowers plasma glucose levels in both rodents and humans, and has a longer-lasting effect than GLP-1. However, since exendin-4 is not naturally present in mammals, it may possess antigenic properties in mammals that are not present in GLP-1. [Overview of the project] [Problems that the invention aims to solve]
[0007] In addition to the decrease in insulin production in diabetes, peripheral neuropathy and diabetes are interconnected. 20–30 percent of all diabetic patients eventually develop peripheral neuropathy. Furthermore, it has been reported that Alzheimer's disease patients have a higher risk of developing heart disease, stroke, hypertension, and diabetes (Moceri et al., 2000; Ott et al., 1999). Therefore, diabetes is also associated with neurodegenerative diseases.
[0008] GLP-1 receptors are present in the brains of rodents (Jin et al. 1988, Shughrue et al. 1996, Jia et al. 2015) and humans (Wei and Mojsov 1995, Satoh et al. 2000). The chemical composition of this distribution appears to be generally limited to the hypothalamus, thalamus, brainstem, lateral septum, subfornical organ, and area postretro, with numerous peptide receptors generally present in any of these periventricular regions. However, specific binding sites for GLP-1 have also been detected, albeit at low densities, in the caudate nucleus putamen, cerebral cortex, and cerebellum (Campos et al. 1994, Calvo et al. 1995, and Goke et al. 1995). For example, Lu et al. (2014) reported that GLP-1 receptor expression is found in the amygdala, cerebellum, frontal cortex, hippocampus, hypothalamus, midbrain, medulla, pons, striatum, thalamus, and temporal cortex of Mustela putorius furo (ferret). Brain expression levels of GLP-1 receptors are not affected by aging.
[0009] Furthermore, GLP-1 has been shown to be involved in cognition and behavior (During et al. 2003). In fact, many studies suggest that GLP-1 receptor agonists are a novel treatment option for neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, Huntington's disease, traumatic brain injury, stroke, and peripheral neuropathy. However, drug delivery to the central nervous system (CNS) via the blood-brain barrier (BBB) is a major obstacle to using them to treat CNS-related diseases. For example, GLP-1 has a short half-life of 1-2 minutes, and although GLP-1-transferrin fusion proteins (GLP-1-Tf), which were created to provide resistance to inactivation, have a longer half-life of approximately 2 days than GLP-1, they have not achieved BBB crossing (Kim et al. (2010) and Martin et al. (2012)).
[0010] Furthermore, studies have shown that exendin-4 improves rotarod test results compared to GLP-1-Tf (Martin et al. 2012), and while exendin-4 is known to enter the brain from the bloodstream, its inflow rate is insufficient (Kastin AJ and Akeerstrom V, International Journal of Obesity (2003) 27, 313-318). In addition, studies have shown that administering exenatide once daily for 7 days to an MPTP Parkinson's disease mouse model, along with post-treatment, did not produce any neuroprotective effects (Liu et al. 2015).
[0011] Therefore, in this field, there is a need for methods to treat neurodegenerative states, as well as methods to maintain stable levels of neuroprotective GLP-1 receptor agonists in plasma, thereby promoting and accelerating drug delivery to the central nervous system via the blood-brain barrier (BBB). [Means for solving the problem]
[0012] overview In one aspect of the present disclosure, a method is provided for delivering a neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of a subject. The method comprises the steps of: administering a therapeutically effective amount of a neuroprotective polypeptide into the systemic circulation of a subject using a controlled-release preparation or device that provides sustained release or sustained delivery of the neuroprotective polypeptide, wherein the neuroprotective polypeptide comprises at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation or sustained release of the neuroprotective polypeptide increases the delivery and / or uptake of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of the subject by crossing the blood-brain barrier (BBB) compared to an immediate-release preparation of the neuroprotective peptide.
[0013] In another aspect of the present disclosure, a method is provided for treating a subject having a central nervous system (CNS) related disorder, or for reducing symptoms in a subject requiring reduction of at least one symptom of a CNS related disorder. The method comprises the steps of administering a therapeutically effective amount of a neuroprotective polypeptide into the systemic circulation of a subject using a controlled-release preparation or device that provides sustained release or sustained delivery of the neuroprotective polypeptide, wherein the neuroprotective polypeptide comprises at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation or device increases the delivery of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) by crossing the blood-brain barrier (BBB) of the subject compared to a fast-release preparation of the neuroprotective polypeptide.
[0014] In one aspect of this disclosure, a method is provided for delivering a neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of a subject. This method comprises administering a controlled-release neuroprotective preparation into the systemic circulation of the subject. In one embodiment, the controlled-release neuroprotective preparation comprises at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin (e.g., exendin-4), or a therapeutically effective GLP-1 or exendin analog (e.g., an exendin-4 analog), wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin (e.g., exendin-4), or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of the subject by crossing the blood-brain barrier (BBB) compared to a fast-release preparation of the neuroprotective polypeptide.
[0015] In certain embodiments, the controlled-release preparation is a sustained-release preparation of a neuroprotective polypeptide.
[0016] In other embodiments, the sustained-release preparation comprises a depot preparation for the sustained release of the neuroprotective polypeptide.
[0017] In a specific embodiment, the sustained-release preparation comprises a composition for the sustained release of the neuroprotective polypeptide.
[0018] In additional embodiments, the controlled-release preparation further comprises a biodegradable polymer having a specific viscosity and a coating material, and the bioavailability and sustained release of the neuroprotective polypeptide at an effective concentration continue over a period of time.
[0019] In a specific embodiment, the controlled-release neuroprotective preparation comprises a controlled-release microsphere comprising a core containing the neuroprotective polypeptide and a biodegradable polymer, and a coating layer covering the core.
[0020] In one embodiment, administration of the controlled-release neuroprotective preparation alleviates at least one symptom of at least one CNS-related condition in a subject.
[0021] In further embodiments, the CNS-related condition is selected from the group consisting of Parkinson's disease (PD), traumatic brain injury (TBI), multiple sclerosis, drug addiction, alcohol addiction, neurodegenerative conditions, brain inflammation, Alzheimer's disease (AD), multiple system atrophy, Huntington's disease, chronic traumatic encephalopathy (CTE), motor neuron diseases (such as amyotrophic lateral sclerosis, spinal cord injury, spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)), vascular dementia, Lewy body dementia (DLB), mixed dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, or combinations thereof.
[0022] In a particular embodiment, administration of the controlled-release neuroprotective preparation comprises injection of the controlled-release neuroprotective preparation.
[0023] In additional embodiments, the injection of the controlled-release neuroprotective preparation is by subcutaneous injection. For example, the administration of the controlled-release neuroprotective preparation may include a subcutaneous injection of the controlled-release neuroprotective preparation.
[0024] In another embodiment, administration of a controlled-release neuroprotective preparation stabilizes the concentration of neuroprotective polypeptides in plasma within a range of approximately 50 to 4500 pg / mL.
[0025] In other embodiments, administration of a controlled-release neuroprotective preparation cumulatively increases the concentration of neuroprotective polypeptides in the cerebrospinal fluid (CSF), brain, or combination thereof.
[0026] In specific embodiments, the concentration of neuroprotective polypeptides in CSF is in the range of about 5 to about 400 pg / mL (for example, about 10 to about 400 pg / mL).
[0027] In an additional embodiment, a method is provided for treating subjects with CNS-related disorders or for reducing symptoms in subjects requiring reduction of at least one symptom of a CNS-related disorder. The method comprises administering a therapeutically effective amount of a controlled-release neuroprotective preparation to the subject into the subject's systemic circulation. The controlled-release neuroprotective preparation comprises at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin (e.g., exendin-4), or a therapeutically effective GLP-1 or exendin (e.g., exendin-4) analog, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin (e.g., exendin-4), or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery of the neuroprotective polypeptide to at least a portion of the CNS by crossing the blood-brain barrier of the subject compared to a fast-release preparation of the neuroprotective polypeptide.
[0028] In certain embodiments, the controlled-release preparation is a sustained-release preparation of a neuroprotective polypeptide.
[0029] In other embodiments, the sustained-release preparation includes a depot preparation for sustained release of a neuroprotective polypeptide.
[0030] In an additional embodiment, the sustained-release preparation comprises a composition for the sustained release of a neuroprotective polypeptide.
[0031] In an additional embodiment, the controlled-release preparation further comprises a biodegradable polymer having a specific viscosity and a coating material, wherein the bioavailability and sustained release of the neuroprotective polypeptide at an effective concentration continues over a period of time.
[0032] In a specific embodiment, the controlled-release neuroprotective preparation comprises a core containing a neuroprotective polypeptide, controlled-release microspheres containing a biodegradable polymer, and a coating layer covering the core.
[0033] In one specific embodiment, administration of a controlled-release neuroprotective preparation alleviates at least one symptom of at least one CNS-related condition in the subject.
[0034] In one embodiment, the CNS state is selected from the group consisting of Parkinson's disease (PD), traumatic brain injury (TBI), multiple sclerosis, drug addiction, alcohol addiction, neurodegenerative states, brain inflammation, Alzheimer's disease (AD), multiple system atrophy, Huntington's disease, chronic traumatic encephalopathy, motor neuron diseases (e.g., amyotrophic lateral sclerosis, spinal cord injury, spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)), vascular dementia, Lewy body dementia (DLB), mixed dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, or a combination thereof.
[0035] In further embodiments, administration of the controlled-release neuroprotective preparation includes injection of the controlled-release neuroprotective preparation into a subject.
[0036] In certain embodiments, the injection of the control-release neuroprotective preparation into the subject is by subcutaneous injection.
[0037] In an additional embodiment, administration of the controlled-release preparation stabilizes the concentration of neuroprotective polypeptides in plasma within a range of approximately 50 to approximately 4500 pg / mL.
[0038] In some embodiments, administration of a controlled-release preparation cumulatively increases the concentration of neuroprotective polypeptides in at least one of the following: cerebrospinal fluid (CSF), brain, or a combination thereof.
[0039] In a further embodiment, a method is provided for delivering a neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of a subject. This method comprises providing sustained delivery of at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog to the systemic circulation of the subject, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery and / or uptake of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of the subject by crossing the blood-brain barrier (BBB) compared to a rapid-release preparation of the neuroprotective peptide.
[0040] In yet another embodiment, a method is provided for treating subjects with central nervous system (CNS)-related disorders or for reducing symptoms in subjects requiring reduction of at least one symptom of a CNS-related disorder. The method comprises providing sustained delivery of at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog to the systemic circulation of the subject, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) by crossing the blood-brain barrier (BBB) of the subject compared to a fast-release preparation of the neuroprotective polypeptide.
[0041] In one embodiment, providing sustained release of (one or more) neuroprotective polypeptides includes administering (one or more) polypeptides by a device (e.g., a pump, minipump, osmotic pump, osmotic delivery device, infusion pump, intravenous administration device, peristaltic pump, or small infusion pump).
[0042] In certain embodiments, the neuroprotective polypeptides (one or more) are administered at a rate of approximately 1 pM / kg / min to approximately 30 pM / kg / min (for example, approximately 3 pM / kg / min to approximately 17.5 pM / kg / min).
[0043] In other embodiments, administration of a controlled-release neuroprotective preparation or provision of sustained delivery of a neuroprotective polypeptide alleviates at least one symptom of at least one CNS-related condition in a subject.
[0044] In specific embodiments, the CNS-related condition is selected from the group consisting of Parkinson's disease (PD), traumatic brain injury (TBI), multiple sclerosis, drug addiction, alcohol addiction, neurodegenerative conditions, brain inflammation, Alzheimer's disease (AD), multiple system atrophy, Huntington's disease, chronic traumatic encephalopathy, motor neuron diseases (e.g., amyotrophic lateral sclerosis, spinal cord injury, spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)), vascular dementia, Lewy body dementia (DLB), mixed dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, or a combination thereof.
[0045] In one embodiment, administration of a controlled-release preparation or provision of sustained release of a neuroprotective polypeptide stabilizes the concentration of the neuroprotective polypeptide in plasma within a range of approximately 50 to approximately 4500 pg / mL.
[0046] In certain embodiments, administration of a controlled-release preparation or provision of sustained release of a neuroprotective polypeptide results in a cumulative increase in the concentration of the neuroprotective polypeptide in at least one of the following: cerebrospinal fluid (CSF), brain, or a combination thereof.
[0047] In yet another embodiment, the concentration of neuroprotective polypeptides in CSF is in the range of about 5 to about 400 pg / mL.
[0048] In some embodiments, the ratio of the polypeptide concentration in stable CFS to the polypeptide concentration in stable plasma is in the range of about 0.1% to about 5%.
[0049] In further embodiments, the neuroprotective polypeptide is selected from the group consisting of SEQ ID NOs: 1 to 55. For example, the neuroprotective polypeptide may contain an amino acid sequence selected from SEQ ID NOs: 1 to 55.
[0050] In other embodiments, the exendin-4 analog is represented by chemical formula I or a pharmaceutically acceptable salt thereof: Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala Xaa27 Xaa28 -Z1 (Chemical formula I) (In the formula, Xaa1 is His, Arg, Tyr, Ala, Norval, Val, Norleu, or 4-imidazopropionyl. Xaa2 is Ser, Gly, Ala, or Thr. Xaa3 is Ala, Asp, or Glu. Xaa4 is Ala, Norval, Val, Norleu, or Gly. Xaa5 is Ala or Thr, Xaa6 is Ala, Phe, Tyr, or naphthylalanine. Xaa7 is either Thr or Ser. Xaa8 is Ala, Ser, or Thr. Xaa9 is Ala, Norval, Val, Norleu, Asp, or Glu. Xaa10 is Ala, Leu, Ile, Val, pentylglycine, or Met. Xaa11 is either Ala or Ser. Xaa12 is either Ala or Lys. Xaa13 is Ala or Gln, Xaa14 is Ala, Leu, Ile, pentylglycine, Val, or Met. Xaa15 is either Ala or Glu. Xaa16 is either Ala or Glu. Xaa17 is either Ala or Glu. Xaa19 is either Ala or Val. Xaa20 is Ala or Arg. Xaa21 is Ala, Leu, or Lys-NHε-R, where R is Lys, Arg, or a linear or branched alkanoyl having 1 to 10 carbon atoms. Xaa22 is Ala, Phe, Tyr, or naphthylalanine. Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met. Xaa24 is Ala, Glu, or Asp. Xaa25 is Ala, Trp, Phe, Tyr, or naphthylalanine. Xaa26 is either Ala or Leu. Xaa27 is either Ala or Lys. Xaa28 is either Ala or Asn, and Z1 is -OH, -NH2, Gly-Z2, Gly Gly-Z2, Gly Gly Xaa31-Z2, Gly Gly Xaa31 Ser-Z2, Gly Gly Xaa31 Ser Ser-Z2, Gly Gly Xaa31 Ser Ser Gly-Z2, Gly Gly Xaa31 Ser Ser Gly Ala-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2, or Gly Gly Xaa31 Ser Ser Gly Ala Xaa31, Xaa36, Xaa37, and Xaa38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine, or N-alkylalanine, and Xaa39 is Ser or Tyr (for example, Ser), and Z2 is -OH or -NH2. however, Of Xaa3, Xaa4, Xaa5, Xaa6, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27, and Xaa28, no more than three are Ala, and If Xaa1 is His, Arg, or Tyr, then at least one of Xaa3, Xaa4, and Xaa9 is Ala.
[0051] In other embodiments, the exendin-4 analog is represented by chemical formula II or a pharmaceutically acceptable salt thereof: Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala X1-Z1 (Chemical formula II) (In the formula, Xaa1 is His, Arg, Tyr, Ala, Norval, Val, Norleu, or 4-imidazopropionyl. Xaa2 is Ser, Gly, Ala, or Thr. Xaa3 is Ala, Asp, or Glu. Xaa4 is Ala, Norval, Val, Norleu, or Gly. Xaa5 is Ala or Thr, Xaa6 is Ala, Phe, Tyr, or naphthylalanine. Xaa7 is either Thr or Ser. Xaa8 is Ala, Ser, or Thr. Xaa9 is Ala, Norval, Val, Norleu, Asp, or Glu. Xaa10 is Ala, Leu, Ile, Val, pentylglycine, or Met. Xaa11 is either Ala or Ser. Xaa12 is either Ala or Lys. Xaa13 is Ala or Gln, Xaa14 is Ala, Leu, Ile, pentylglycine, Val, or Met. Xaa15 is either Ala or Glu. Xaa16 is either Ala or Glu. Xaa17 is either Ala or Glu. Xaa19 is either Ala or Val. Xaa20 is either Ala or Arg. Xaa21 is Ala, Leu, or Lys-NHε-R (where R is Lys, Arg, a linear or branched alkanoyl having 1 to 10 carbon atoms, or a cycloaleyl-alkanoyl), Xaa22 is Phe, Tyr, or naphthylalanine. Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met. Xaa24 is Ala, Glu, or Asp. Xaa25 is Ala, Trp, Phe, Tyr, or naphthylalanine. Xaa26 is either Ala or Leu. X1 is Lys Asn, Asn Lys, Lys-NHε-R Asn, Asn Lys-NHε-R, Lys-NHε-R Ala, Ala Lys-NHε-R, where R is Lys, Arg, a linear or branched alkanoyl having 1 to 10 carbon atoms, or a cycloalkyl alkanoyl. Z1 is -OH, -NH2, Gly-Z2, Gly Gly-Z2, Gly Gly Xaa31-Z2, Gly Gly Xaa31 Ser-Z2, Gly Gly Xaa31 Ser Ser-Z2, Gly Gly Xaa31 Ser Ser Gly-Z2, Gly Gly Xaa31 Ser Ser Gly Ala-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2, or Gly Gly Xaa31 Ser Ser Gly Ala Xaa31, Xaa36, Xaa37, and Xaa38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine, and N-alkylalanine, and Xaa39 is Ser or Tyr, and Z2 is -OH or -NH2), however, Of Xaa3, Xaa4, Xaa5, Xaa6, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, and Xaa26, no more than three are Ala, and If Xaa1 is His, Arg, Tyr, or 4-imidazopropionyl, then at least one of Xaa3, Xaa4, and Xaa9 is Ala.
[0052] The accompanying drawings are incorporated herein and constitute part of this specification, and are intended to illustrate one or more embodiments of this disclosure, and together with the description herein, serve to illustrate the principles of this disclosure. [Brief explanation of the drawing]
[0053] [Figure 1A] This graph shows the time-dependent plasma levels of exenatide (exendin-4) after a single subcutaneous administration of sustained-release exenatide (PT302) at a dose of 2 mg / kg to adult (9-week-old) male Sprague-Dawley rats. [Figure 1B] This graph shows the time-dependent plasma levels of exenatide (exendin-4) after a single subcutaneous administration of sustained-release exenatide (PT302) at doses of 2.4 mg / kg, 4.8 mg / kg, or 9.6 mg / kg to adult (9-week-old) male Sprague-Dawley rats. [Figure 2] This graph shows the time-dependent exendin-4 plasma levels after a single subcutaneous injection of sustained-release exenatide (PT304) at a dose of 4.0 mg / kg into adult (9-week-old) male Sprague-Dawley rats. [Figure 3] This graph shows the time-dependent exendin-4 plasma levels over 10 weeks in male Sprague-Dawley rats administered either PT302 or PT304 at the stated doses and frequencies. [Figure 4A] The experimental design for Example 2 is outlined below. Sprague-Dawley rats were administered PT302 before inducing unilateral damage to the medial forebrain bundle with 6-OHDA. [Figure 4B] This graph shows the methamphetamine-induced (meth-induced) circling behavior of 6-OHDA rats pretreated with PT302. [Figure 4C] This graph shows the plasma levels of exendin-4 in 6-OHDA rats pretreated with PT302. [Figure 5A] The experimental design for Example 3 is outlined below. Sprague-Dawley rats were subjected to unilateral injury of the medial forebrain bundle with 6-OHDA, followed by administration of PT302. [Figure 5B] This graph shows the meth-induced circling behavior of 6-OHDA rats post-treatment with PT302. [Figure 5C] These are representative microscopic images of rats that underwent unilateral injury to the medial forebrain bundle with 6-OHDA, administered a vehicle (control) (rats #866, #883, and #886) and PT302 (rats #881, #875, and #882), and then underwent tyrosine hydroxylase (TH) immunohistochemical examination of the striae. The exendin-4 plasma concentration (ng / ml) for each animal is shown. [Figure 5D] This graph shows the quantitative results of TH immunoreactivity observed in immunohistochemical tests described in and related to Figure 5C. [Figure 5E] These are representative microscopic images of rats that underwent unilateral injury to the medial forebrain bundle with 6-OHDA, administered a vehicle (control) (rats #866, #883, and #886) and PT302 (rats #881, #875, and #882), and underwent TH immunohistochemical examination of the substantia nigra. The exendin-4 plasma concentration (ng / ml) for each animal is shown. [Figure 5F] This graph shows the quantitative results of TH immunoreactivity observed in immunohistochemical tests described in and related to Figure 5E. [Figure 5G] This is a representative microscopic image of TH+ neurons observed on the uninjured side of a rat brain. [Figure 5H] This is a representative microscopic image of TH+ neurons observed on the uninjured side of a rat brain. [Figure 5I] This is a representative microscopic image showing the absence of TH+ neurons in the substantia nigra on the injured side of the brain of a rat that was unilaterally injured in the medial forebrain bundle with 6-OHDA. [Figure 5J] This is a representative image of the brain of a 6-OHDA rat treated with PT302. [Figure 5K] This is a representative image of the brain of a 6-OHDA rat treated with PT302. [Figure 5L] This is a representative image of the brain of a 6-OHDA rat treated with PT302. [Figure 5M] This graph shows the significant correlation observed between standardized TH immunoreactivity and exendin-4 plasma levels (in the striae). [Figure 5N] This graph shows the significant correlation observed between exendin-4 plasma levels and TH immunoreactivity in the substantia nigra. [Figure 6A] The experimental design for Example 4 is outlined below. [Figure 6B] In rats induced with 6-OHDA, unilateral injury to the medial forebrain bundle was reduced by treatment with ecsendin-4 and PT302. [Figure 6C] These are representative microscopic images of the substantia nigra from control (sham) rats, 6-OHDA rats, exendin-4 treated 6-OHDA rats, and PT302 treated 6-OHDA rats. [Figure 6D] This graph shows the quantified data from Figure 6C. [Figure 7A] The experimental design for Example 5 is outlined below. [Figure 7B] The circling behavior of rats with unilateral 6-OHDA injury was significantly reduced by PT302, but it was not reduced by exendin-4. [Figure 8A] The experimental design for Example 6 is outlined below. [Figure 8B] This graph shows that the time it takes for MPTP-treated mice to fall off the wire is significantly increased with PT302, but not with exendin-4. [Figure 9A] The experimental design for Example 8 is outlined below. [Figure 9B] This graph shows that novel object recognition was significantly increased in mice induced with mild traumatic brain injury (mTBI) by sustained-release exenatide. [Figure 10A] This graph shows that exendin-4 plasma levels persist for 7 days after PT302 administration and are also dose-dependent. [Figure 10B] This graph shows that no significant difference in exendin-4 plasma levels derived from PT302 administration was observed between normal / control mice and mTBI-treated mice. [Figure 10C] This graph shows that three different doses of sustained-release exenatide (PT302, 0.024, 0.12, and 0.6 mg / kg) could be accumulated in plasma and maintained in a time-dependent manner in plasma. [Figure 11A] This graph shows that sustained-release exenatide (PT302, 0.024, 0.12, and 0.6 mg / kg) increased preference for new objects in mTBI-treated mice, while untreated mTBI-treated mice exhibited visual memory deficits and shorter time spent near new objects. The evaluation was performed 7 days after mTBI using a novel object recognition paradigm. [Figure 11B] This graph shows that the mTBI spatial memory deficit observed in untreated mTBI-treated mice was resolved by sustained-release exenatide (PT302, 0.024, 0.12, and 0.6 mg / kg). The evaluation was performed using a Y-maze 7 days after mTBI. [Figure 11C] These graphs show that the results in Figures 11A and 11B were not the result of anxiety-like behavior. [Figure 12A] This graph shows that sustained-release exenatide (PT302, 0.12 and 0.6 mg / kg) increased preference for new objects in mTBI-induced mice, while untreated mTBI-induced mice exhibited visual memory deficits and reduced time spent near new objects. The evaluation was performed 30 days after mTBI using a novel object recognition paradigm. [Figure 12B] This graph shows that the mTBI spatial memory deficit observed in untreated mTBI-induced mice was remitted with sustained-release exenatide (PT302, 0.12 and 0.6 mg / kg). The evaluation was performed using a Y-maze 30 days after mTBI. [Figure 12C] These graphs show that the results in Figures 12A and 12B were not the result of anxiety-like behavior. [Figure 13A] This is a representative image demonstrating that the neuronal reduction observed in the cortex, CA3, and dentate gyrus of mTBI-induced mice could be prevented by sustained-release exenatide (PT302, 0.6 mg / kg). [Figure 13B] This graph quantifies cortical data associated with a representative image in Figure 13A. The graph shows that the neuronal reduction observed in the cerebral cortex of mTBI-induced mice could be prevented by sustained-release exenatide (PT302, 0.6 mg / kg). [Figure 13C] This graph quantifies CA3 data related to a representative image in Figure 13A. The graph shows that the decrease in neurons observed in the CA3 region of the hippocampus of mTBI-induced mice could be prevented by sustained-release exenatide (PT302, 0.6 mg / kg). [Figure 13D] This graph quantifies data for the dentate gyrus associated with a representative image in Figure 13A. The graph shows that the decrease in neurons observed in the dentate gyrus region of the hippocampus of mTBI-induced mice could be prevented by sustained-release exenatide. [Figure 14A] Representative images of Fluoro-Jade® C staining, a marker of neuronal reduction due to brain injury, are shown in control (CTRL) mice given vehicle or sustained-release exenatide (0.6 mg / kg or 0.12 mg / kg (PT302)) and mTBI-treated mice. [Figure 14B] This graph quantifies data from the hippocampal CA1 region associated with the representative image in Figure 14A. It shows that the significant increase in neuronal reduction due to traumatic brain injury in CA1 of untreated mTBI-induced mice was significantly reduced by administration of sustained-release exenatide (PT302) at 0.6 mg / kg. [Figure 14C] This graph quantifies data from the hippocampal CA3 region associated with the representative image in Figure 14A. It shows that the significant increase in neuronal reduction due to traumatic brain injury in the CA3 region of untreated mTBI-induced mice was significantly reduced by administration of sustained-release exenatide (PT302) at 0.6 mg / kg or 0.12 mg / kg. [Figure 14D] This graph quantifies data for the dentate gyrus associated with the representative image in Figure 14A. It shows that the significant increase in neuronal reduction due to traumatic brain injury in the dentate gyrus of untreated mTBI-induced mice was significantly reduced by administration of sustained-release exenatide (PT302) at 0.6 mg / kg or 0.12 mg / kg. [Figure 14E] This graph quantifies cortical data related to the representative image in Figure 14A. It shows that the significant increase in neuronal reduction due to traumatic brain injury in the cortex of untreated mTBI-induced mice was significantly reduced by administration of sustained-release exenatide (PT302) at 0.6 mg / kg. [Figure 15A] Representative images of ionized calcium-binding adapter molecule 1 (IBA1) staining, a marker of microglial activation and neuroinflammation (resulting from traumatic brain injury), are shown in control and mTBI-induced mice administered with either a vehicle or sustained-release exenatide (PT302) (0.6 mg / kg or 0.12 mg / kg). [Figure 15B] This graph quantifies CA1 data related to the representative image in Figure 15A. It shows that pro-inflammatory cytokine TNF-α was significantly increased in IBA1+ cells in CA1 of untreated mTBI-induced mice, and this was significantly reduced by administration of sustained-release exenatide (PT302) at 0.6 mg / kg or 0.12 mg / kg. [Figure 15C] This graph quantifies CA3 data related to the representative image in Figure 15A. It shows that pro-inflammatory cytokine TNF-α was significantly increased in IBA1+ cells in CA3 of untreated mTBI-induced mice, and this was significantly reduced by administration of sustained-release exenatide (PT302) at 0.6 mg / kg or 0.12 mg / kg. [Figure 15D] This graph quantifies data for the dentate gyrus associated with the representative image in Figure 15A. It shows that the pro-inflammatory cytokine TNF-α was significantly increased in IBA1+ cells in the dentate gyrus of untreated mTBI-induced mice, but this was significantly reduced by administration of sustained-release exenatide (PT302) at 0.6 mg / kg or 0.12 mg / kg. [Figure 15E] This graph quantifies cortical data associated with the representative image in Figure 15A. It shows that the pro-inflammatory cytokine TNF-α was significantly increased in IBA1+ cells in the cortex of untreated mTBI-induced mice, but this was significantly reduced by administration of sustained-release exenatide at 0.6 mg / kg or 0.12 mg / kg. [Modes for carrying out the invention]
[0054] Detailed explanation This disclosure is based on the surprisingly unexpected increase in the delivery of the active ingredients described herein (e.g., GLP-1, exendin, and bioactive analogs or derivatives of GLP-1 and exendin). The contents described herein will be more readily understood by referring to the detailed description of preferred embodiments of this disclosure and the examples included herein, as well as by referring to the drawings and the descriptions before and after the drawings.
[0055] Prior to the disclosure and description of the compounds, compositions, articles, devices, and / or methods of the present invention, it is understood that this disclosure is not limited to any particular synthesis method, any particular treatment plan, or any specific purification procedure, and therefore may be diverse, needless to say. It is also understood that the purpose of using technical terms herein is solely to describe specific embodiments and not to limit them.
[0056] All publications, patent applications, patents, and other prior art documents referenced herein are incorporated herein by reference in their entirety. For example, U.S. Patent Nos. 8,853,160, 8,278,272, 7,576,050, 9,155,702, International Patent Publication No. WO / 2003 / 011892, and the works of Gu et al. (Clinical Therapeutics. 36(1):101-114(2014)) are each incorporated herein by reference for any purpose.
[0057] As used herein and in the accompanying claims, the singular forms "a," "an," and "the" also include plural meanings unless otherwise specified. For example, the term "polypeptide" includes a mixture of several types of polypeptides, and the term "pharmaceutical carrier" includes a mixture of two or more types of pharmaceutical carriers.
[0058] In this specification, a range may be expressed as "approximately" a specific value to "approximately" another specific value. When a range is expressed in this manner, it is understood that in another embodiment, the range from the above specific value to the above another specific value is included. Similarly, when a value is expressed as an approximation with "approximately" preceding it, it is understood that the specific value constitutes another embodiment. Furthermore, for each range, it is understood that one endpoint has meaning in relation to the other endpoint, and also has meaning independently of the other endpoint. As used in this specification, "approximately" refers to ±10% of a given value.
[0059] Many terms that may be referenced in this specification and in the claims thereafter are defined as having the following meanings:
[0060] "Optional" or "optional" means that the event or situation described thereafter may or may not occur. This description includes cases where such event or situation occurs and cases where it does not.
[0061] Throughout this specification, “subject” means an individual; in certain embodiments, the subject is a mammal such as a primate. In one specific embodiment, the subject is a human. Therefore, “subject” may include domesticated animals such as cats and dogs, livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mice, rabbits, rats, guinea pigs, etc.).
[0062] The terms “polypeptide” and “peptide” are generally used interchangeably unless otherwise specified. Unless otherwise specified, “polypeptide” and “peptide” may both refer to natural or non-natural amino acids linked by peptide bonds.
[0063] The term “stable state” is used in its usual sense in pharmacokinetics. Briefly, the stable state concentration, for example, in plasma or cerebrospinal fluid (CSF), is the concentration in plasma and CSF at which the rate at which the neuroprotective polypeptide (one or more) is administered is equal to the rate at which it is eliminated from the subject's body. Determining the stable state concentration of the neuroprotective polypeptide (one or more) relating to this disclosure is a standard practice for those skilled in the art.
[0064] "Isolated polypeptide" or "purified polypeptide" means that, for a polypeptide, it substantially does not contain substances that are normally bound to that polypeptide in nature or under culture. Polypeptides relating to this disclosure may be obtained, for example, by extraction from a natural product (e.g., mammalian cells) if such a natural product is available, by expression from a recombinant nucleic acid encoding the polypeptide (e.g., in cells or in a cell-free translation system), or by chemical synthesis of the polypeptide. Polypeptides may also be obtained by cleaving a full-length polypeptide. If the polypeptide is a fragment of a large natural polypeptide, the isolated polypeptide will be shorter than the full-length natural polypeptide before fragmentation, and the isolated polypeptide will not contain the full-length natural polypeptide before fragmentation.
[0065] This disclosure relates to a method for delivering a neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of a subject. The method comprises administering a controlled-release neuroprotective preparation into the systemic circulation of the subject, the controlled-release neuroprotective preparation comprising at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin (e.g., exendin-4), or a therapeutically effective GLP-1 or exendin analog (e.g., exendin-4 analog), the neuroprotective polypeptide binding to and activating a receptor that binds to at least one of GLP-1, exendin (e.g., exendin-4), or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of the subject by crossing the blood-brain barrier (BBB) compared to a fast-release preparation of the neuroprotective polypeptide.
[0066] As shown in Figures 1A, 1B, 2, and 3, controlled-release neuroprotective preparations better maintain exenatide plasma levels in animal models. Furthermore, Figures 7B and 8B demonstrate that controlled-release preparations of exenatide are preparations and / or treatments with enhanced neuroprotective and neuroregenerative effects compared to exenatide alone.
[0067] This disclosure relates to a method for delivering a neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of a subject. The method may include administering a therapeutically effective amount of a neuroprotective polypeptide into the systemic circulation of a subject using a controlled-release preparation or device that provides sustained release or sustained delivery of the neuroprotective polypeptide, wherein the neuroprotective polypeptide comprises at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and controlled-release neuroprotective preparations or sustained release of neuroprotective polypeptides increase the delivery and / or uptake of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of a subject by crossing the blood-brain barrier (BBB) compared to immediate-release preparations of neuroprotective peptides.
[0068] The disclosure also relates to methods for treating subjects with central nervous system (CNS) related disorders or for reducing symptoms in subjects requiring reduction of at least one symptom of a CNS related disorder. The method may include administering a therapeutically effective amount of a neuroprotective polypeptide into the systemic circulation of a subject using a controlled-release preparation or device that provides sustained release or sustained delivery of the neuroprotective polypeptide, wherein the neuroprotective polypeptide comprises at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation or device increases the delivery of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) by crossing the blood-brain barrier (BBB) of the subject compared to a rapid-release preparation of the neuroprotective polypeptide.
[0069] In certain embodiments, the controlled-release preparation is a sustained-release preparation of a neuroprotective polypeptide. The sustained-release preparation may include a depot preparation for the sustained release of the neuroprotective polypeptide. For example, the sustained-release preparation may include a composition for the sustained release of the neuroprotective polypeptide (details are described below). In additional embodiments, the controlled-release preparation further comprises a biodegradable polymer having a specific viscosity and a coating material, wherein the bioavailability and sustained release of the neuroprotective polypeptide at an effective concentration continues over a period of time. In additional embodiments, the controlled-release preparation further comprises a biodegradable polymer having a specific viscosity and a coating material, wherein the bioavailability and sustained release of the neuroprotective polypeptide at an effective concentration continues over a period of time without causing an initial burst of the active ingredient (e.g., an initial burst of the active ingredient, such as a harmful initial burst). In specific embodiments, the controlled-release neuroprotective preparation comprises a core containing the neuroprotective polypeptide, controlled-release microspheres containing a biodegradable polymer, and a coating layer covering the core.
[0070] In one embodiment, administration of a controlled-release neuroprotective preparation alleviates at least one symptom of at least one CNS-related condition in the subject. For example, the CNS-related conditions may be selected from the group consisting of Parkinson's disease (PD), traumatic brain injury (TBI), multiple sclerosis, drug addiction, alcohol addiction, neurodegenerative conditions, brain inflammation, Alzheimer's disease (AD), multiple system atrophy, Huntington's disease, chronic traumatic encephalopathy, motor neuron diseases (e.g., amyotrophic lateral sclerosis, spinal cord injury, spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)), vascular dementia, Lewy body dementia (DLB), mixed dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, or a combination thereof.
[0071] Administration of a controlled-release neuroprotective preparation may include injection of the controlled-release neuroprotective preparation. For example, the controlled-release neuroprotective preparation may be administered by subcutaneous injection.
[0072] In another embodiment, administration of a controlled-release neuroprotective preparation stabilizes the concentration of neuroprotective polypeptides in plasma within the range of approximately 50 to 4500 pg / mL. For example, the concentration of neuroprotective polypeptides in plasma in this stable state is approximately 50 to 4500 pg / mL, approximately 50 to 4250 pg / mL, approximately 50 to 4000 pg / mL, approximately 50 to 3750 pg / mL, approximately 50 to 3500 pg / mL, approximately 50 to 3250 pg / mL, approximately 50 to 3000 pg / mL, approximately 50 to 2750 pg / mL, approximately 50 to 2500 pg / mL, approximately 50 to 2250 pg / mL, approximately 50 to 2000 pg / mL, approximately 50 to 1750 pg / mL, approximately 50 to 1500 pg / mL, and approximately 5 0 to about 1250 pg / mL, about 50 to about 1000 pg / mL, about 50 to about 750 pg / mL, about 50 to about 500 pg / mL, about 50 to about 250 pg / mL, about 250 to about 4500 pg / mL, about 250 to about 4250 pg / mL, about 250 to about 4000 pg / mL mL, about 250 to about 3750 pg / mL, about 250 to about 3500 pg / mL, about 250 to about 3250 pg / mL, about 250 to about 3000 pg / mL, about 250 to about 2750 pg / mL, about 250 to about 2500 pg / mL, about 250 to about 2250 pg / mL, About 250 to about 2000 pg / mL, about 250 to about 1750 pg / mL, about 250 to about 1500 pg / mL, about 250 to about 1250 pg / mL, about 250 to about 1000 pg / mL, about 250 to about 750 pg / mL, about 250 to about 500 pg / mL, about 500 to about Approximately 4500pg / mL, approximately 500 to approximately 4250pg / mL, approximately 500 to approximately 4000pg / mL, approximately 500 to approximately 3750pg / mL, approximately 500 to approximately 3500pg / mL, approximately 500 to approximately 3250pg / mL, approximately 500 to approximately 3000pg / mL, approximately 500 to approximately 27 50pg / mL, about 500 to about 2500pg / mL, about 500 to about 2250pg / mL, about 500 to about 2000pg / mL, about 500 to about 1750pg / mL, about 500 to about 1500pg / mL, about 500 to about 1250pg / mL, about 500 to about 1000p g / mL, about 500 to about 750 pg / mL, about 750 to about 4500 pg / mL, about 750 to about 4250 pg / mL, about 750 to about 4000 pg / mL, about 750 to about 3750 pg / mL, about 750 to about 3500 pg / mL, about 750 to about 3250 pg / mL,Approximately 750–3000 pg / mL, approximately 750–2750 pg / mL, approximately 750–2500 pg / mL, approximately 750–2250 pg / mL, approximately 750–2000 pg / mL, approximately 750–1750 pg / mL, approximately 750–1500 pg / mL, approximately 750–1250 pg / mL, approximately 750–1000 pg / mL, approximately 1000–4500 pg / mL, approximately 1000–4250 pg / mL, approximately 1000–4000 pg / mL, approximately 1000–3750 pg / mL, approximately 1000–3500 pg / mL, approximately 1000–3250 pg / mL, approximately 1 000~approx. 3000 pg / mL, approx. 1000~approx. 2750 pg / mL, approx. 1000~approx. 2500 pg / mL, approx. 1000~approx. 2250 pg / mL, approx. 1000~approx. 2000 pg / mL, approx. 1000~approx. 1750 pg / mL, approx. 1000~approx. 1500 pg / mL, approx. 1000~approx. 1250 pg / mL, approx. 1250~approx. 4500 pg / mL, approx. 1250~approx. 4250 pg / mL, approx. 1250~approx. 4000 pg / mL, approx. 1250~approx. 3750 pg / mL, approx. 1250~approx. 3500 pg / mL, approx. 1250~approx. 3250 pg / mL, approx. 1250~approx. 3000 pg / mL / mL, approximately 1250 to approximately 2750 pg / mL, approximately 1250 to approximately 2500 pg / mL, approximately 1250 to approximately 2250 pg / mL, approximately 1250 to approximately 2000 pg / mL, approximately 1250 to approximately 1750 pg / mL, approximately 1250 to approximately 1500 pg / mL, approximately 1500 to approximately 4500 pg / mL, approximately 1500 to approximately 4250 pg / mL, approximately 1500 to approximately 4000 pg / mL, approximately 1500 to approximately 3750 pg / mL, approximately 1500 to approximately 3500 pg / mL, approximately 1500 to approximately 3250 pg / mL, approximately 1500 to approximately 3000 pg / mL, approximately 1500 to approximately 2750 pg / mL, approximately 1500 to Approximately 2500 pg / mL, approximately 1500–2250 pg / mL, approximately 1500–2000 pg / mL, approximately 1500–1750 pg / mL, approximately 1750–4500 pg / mL, approximately 1750–4250 pg / mL, approximately 1750–4000 pg / mL, approximately 1750–3750 pg / mL, approximately 1750–3500 pg / mL, approximately 1750–3250 pg / mL, approximately 1750–3000 pg / mL, approximately 1750–2750 pg / mL, approximately 1750–2500 pg / mL, approximately 1750–2250 pg / mL, approximately 1750–2000 pg / mLAbout 2000 to about 4500 pg / mL, about 2000 to about 4250 pg / mL, about 2000 to about 4000 pg / mL, about 2000 to about 3750 pg / mL, about 2000 to about 3500 pg / mL, about 2000 to about 3250 pg / mL, about 20 00 to about 3000 pg / mL, about 2000 to about 2750 pg / mL, about 2000 to about 2500 pg / mL, about 2000 to about 2250 pg / mL, about 2250 to about 4500 pg / mL, about 2250 to about 4250 pg / mL, about 2250 to about 4000pg / mL, about 2250 to about 3750pg / mL, about 2250 to about 3500pg / mL, about 2250 to about 3250pg / mL, about 2250 to about 3000pg / mL, about 2250 to about 2750pg / mL, about 2250 to about 250 0pg / mL, about 2500 to about 4500pg / mL, about 2500 to about 4250pg / mL, about 2500 to about 4000pg / mL, about 2500 to about 3750pg / mL, about 2500 to about 3500pg / mL, about 2500 to about 3250pg / mL mL, about 2500 to about 3000 pg / mL, about 2500 to about 2750 pg / mL, about 2750 to about 4500 pg / mL, about 2750 to about 4250 pg / mL, about 2750 to about 4000 pg / mL, about 2750 to about 3750 pg / mL, About 2750 to about 3500 pg / mL, about 2750 to about 3250 pg / mL, about 2750 to about 3000 pg / mL, about 3000 to about 4500 pg / mL, about 3000 to about 4250 pg / mL, about 3000 to about 4000 pg / mL, about 300 The range may be 0 to approximately 3750 pg / mL, approximately 3000 to approximately 3500 pg / mL, approximately 3000 to approximately 3250 pg / mL, approximately 3250 to approximately 4500 pg / mL, approximately 3250 to approximately 4250 pg / mL, approximately 3250 to approximately 4000 pg / mL, approximately 3250 to approximately 3750 pg / mL, approximately 3250 to approximately 3500 pg / mL, approximately 3500 to approximately 4500 pg / mL, approximately 3500 to approximately 4250 pg / mL, approximately 3500 to approximately 4000 pg / mL, or approximately 3500 to approximately 3750 pg / mL.
[0073] As described above, the sustained and stable concentration of neuroprotective polypeptides in plasma leads to a cumulative increase in the concentration of neuroprotective polypeptides in the target cerebrospinal fluid (CSF), brain, or combination thereof. For example, the concentration of neuroprotective polypeptides in CSF may be in the range of approximately 5 to approximately 400 pg / mL or approximately 10 to approximately 400 pg / mL. In other words, the concentrations of neuroprotective polypeptides in CSF are approximately 10–350 pg / mL, 10–300 pg / mL, 10–250 pg / mL, 10–200 pg / mL, 10–150 pg / mL, 10–100 pg / mL, 10–50 pg / mL, 50–400 pg / mL, 50–350 pg / mL, 50–300 pg / mL, 50–250 pg / mL, 50–200 pg / mL, 50–150 pg / mL, 50–100 pg / mL, 100–400 pg / mL, 100–350 pg / mL, 100–300 pg / mL, and 100–250 pg / mL. pg / mL, about 100 to about 200 pg / mL, about 100 to about 150 pg / mL, about 150 to about 400 pg / mL, about 150 to about 350 pg / mL, about 1 50 to about 300 pg / mL, about 150 to about 250 pg / mL, about 150 to about 200 pg / mL, about 200 to about 400 pg / mL, about 200 to about 350 pg The values may be within the range of / mL, approximately 200 to approximately 300 pg / mL, approximately 200 to approximately 250 pg / mL, approximately 250 to approximately 400 pg / mL, approximately 250 to approximately 350 pg / mL, approximately 250 to approximately 300 pg / mL, approximately 300 to approximately 400 pg / mL, approximately 300 to approximately 350 pg / mL, or approximately 350 to approximately 400 pg / mL.
[0074] In any embodiment or aspect described herein, the ratio of the concentration of polypeptide in stable CSF to the concentration of polypeptide in stable plasma may be in the range of about 0.1% to about 5%. For example, the ratio of the concentration of polypeptide in stable CSF to the concentration of polypeptide in stable plasma may be at least about 0.1%, at least about 0.3%, at least about 0.5%, at least about 0.7%, at least about 0.9%, at least about 1%, at least about 1.1%, at least about 1.2%, at least about 1.5%, and at least It may also be approximately 2.0%, approximately 0.1% to approximately 5%, approximately 0.1% to approximately 4%, approximately 0.1% to approximately 3%, approximately 0.1% to approximately 2%, approximately 0.5% to approximately 5%, approximately 0.5% to approximately 4%, approximately 0.5% to approximately 3%, approximately 0.5% to approximately 2%, approximately 1% to approximately 5%, approximately 1% to approximately 4%, approximately 1% to approximately 3%, approximately 1% to approximately 2%, approximately 2% to approximately 5%, approximately 2% to approximately 4%, approximately 2% to approximately 3%, approximately 3% to approximately 5%, approximately 3% to approximately 4%, or approximately 4% to approximately 5%.
[0075] In any embodiment or configuration described herein, the percentage change in the concentration level of the neuroprotective polypeptide in plasma at a stable state (i.e., the percentage change after reaching a stable state) may be about 80% or less (e.g., about 50% or less). For example, if a re-administration is performed after reaching a stable plasma level and / or concentration, the percentage change in the concentration of the neuroprotective polypeptide in plasma may be about 80% or less (e.g., about 50% or less) (for example, the concentration of the neuroprotective polypeptide in plasma may stabilize about 2, 3, 4, 5, or 6 weeks after the first administration).For example, the percentage change in the concentration of neuroprotective polypeptides in plasma at a stable state after reaching a stable state is, for example, when the neuroprotective polypeptide is re-administered within approximately 28 days (e.g., within approximately 7, 14, or 21 days) of the preceding administration of the neuroprotective polypeptide (e.g., within approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 days) of the preceding administration of one or more neuroprotective polypeptides. (If administered approximately 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days later), approximately 80% or less, approximately 79% or less, approximately 78% or less, approximately 77% or less, approximately 76% or less, approximately 75% or less, approximately 74% or less, approximately 73% or less, approximately 72% or less, approximately 71% or less, approximately 70% or less, approximately 69% or less, approximately 68% or less, approximately 67% or less, approximately 66% or less, approximately 65% or less, approximately 64% or less, approximately 63% or less, approximately 6 2% or less, 61% or less, 60% or less, 59% or less, 58% or less, 57% or less, 56% or less, 55% or less, 54% or less, 53% or less, 52% or less, 51% or less, 50% or less, 49% or less, 48% or less Lower, about 47% or less, about 46% or less, about 45% or less, about 44% or less, about 43% or less, about 42% or less, about 41% or less, about 40% or less, about 39% or less, about 39% or less, about 37% or less, about 36% or less, about 35% or less, about 34% or less, about The percentages are 33% or less, approximately 32% or less, approximately 31% or less, approximately 30% or less, approximately 29% or less, approximately 28% or less, approximately 27% or less, approximately 26% or less, approximately 25% or less, approximately 24% or less, approximately 23% or less, approximately 22% or less, approximately 21% or less, approximately 20% or less, approximately 19% or less, approximately 18% or less, approximately 17% or less, approximately 16% or less, approximately 15% or less, approximately 14% or less, approximately 13% or less, approximately 12% or less, approximately 11% or less, approximately 10% or less, approximately 9% or less, approximately 8% or less, approximately 7% or less, approximately 6% or less, or approximately 5% or less.
[0076] In any embodiment or configuration described herein, the preparation is administered once every 7 to 28 days (for example, every 7 to 21 days or every 7 to 14 days). For example, the preparation may be administered multiple times, with intervals of about 7 to 28 days (for example, once every 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days) (for example, the next dose is administered about 7 to 28 days after the previous dose). The preparation may be administered multiple times in any of the embodiments or models described herein, with intervals between administrations of the preparation being about 7 to about 28 days (for example, intervals of about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, or about 21 days (i.e., once every about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 26, about 27, or about 28 days)).
[0077] In an additional embodiment, a method is provided for treating subjects with central nervous system (CNS)-related disorders or for reducing symptoms in subjects requiring reduction of at least one symptom of a CNS-related disorder. The method comprises administering a therapeutically effective amount of a controlled-release neuroprotective preparation to a subject into the subject's systemic circulation, the controlled-release neuroprotective preparation comprising at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin (e.g., exendin-4), or a therapeutically effective GLP-1 or exendin (e.g., exendin-4) analog, the neuroprotective polypeptide binding to and activating a receptor that binds to at least one of GLP-1, exendin (e.g., exendin-4), or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) by crossing the blood-brain barrier (BBB) of the subject compared to the neuroprotective polypeptide alone.
[0078] In one specific embodiment, administration of a controlled-release neuroprotective preparation alleviates at least one symptom of at least one CNS-related condition in the subject. For example, this CNS condition is selected from the group consisting of Parkinson's disease (PD), traumatic brain injury (TBI), multiple sclerosis, drug addiction, alcohol addiction, neurodegenerative conditions, brain inflammation, Alzheimer's disease (AD), multiple system atrophy, Huntington's disease, chronic traumatic encephalopathy, motor neuron diseases (e.g., amyotrophic lateral sclerosis, spinal cord injury, spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)), vascular dementia, Lewy body dementia (DLB), mixed dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, or a combination thereof.
[0079] In further embodiments, administration of a controlled-release neuroprotective preparation includes injection of the controlled-release neuroprotective preparation into a subject. For example, administration of a controlled-release neuroprotective preparation includes subcutaneous injection of the controlled-release neuroprotective preparation into a subject. In additional embodiments, the controlled-release preparation further comprises a biodegradable polymer having a specific viscosity and a coating material, such that the bioavailability and sustained release of the neuroprotective polypeptide at an effective concentration continues over a period of time. In any aspect or embodiment described herein, the controlled-release preparation provides bioavailability and sustained release of the neuroprotective polypeptide at an effective concentration over a period of time without causing an initial burst of the active ingredient (e.g., a harmful initial burst). In specific embodiments, the controlled-release neuroprotective preparation comprises a core containing the neuroprotective polypeptide, controlled-release microspheres containing a biodegradable polymer, and a coating layer covering the core.
[0080] In an additional embodiment, administration of the controlled-release preparation stabilizes the concentration of the neuroprotective polypeptide in the plasma within the range described above, for example, within the range of about 50 to about 4500 pg / mL.
[0081] In some embodiments, administration of a controlled-release preparation cumulatively increases the concentration of neuroprotective polypeptides in at least one of the following: cerebrospinal fluid (CSF), brain, or a combination thereof.
[0082] In a further embodiment, the Disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of a subject. The method comprises providing sustained delivery of at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog to the systemic circulating blood flow of the subject, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery and / or uptake of the neuroprotective polypeptide to at least a portion of the CNS by crossing the blood-brain barrier (BBB) of the subject compared to a rapid-release preparation of the neuroprotective peptide.
[0083] In yet another embodiment, the Disclosure provides a method for treating a subject having a CNS-related disorder or for reducing symptoms in a subject requiring reduction of at least one symptom of a CNS-related disorder. The method comprises providing sustained delivery of at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog to the systemic circulation of the subject, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery of the neuroprotective polypeptide to at least a portion of the CNS by crossing the blood-barb of the subject compared to a fast-release preparation of the neuroprotective polypeptide. In any aspect or embodiment described herein, providing sustained release of (one or more) neuroprotective polypeptides includes administering (one or more) neuroprotective polypeptides using a device (e.g., a pump, minipump, osmotic pump, osmotic delivery device, infusion pump, intravenous administration device, peristaltic pump, or miniature infusion pump).
[0084] Neuroprotective polypeptides (one or more) (e.g., in the form contained in controlled-release neuroprotective preparations) may be administered at a rate of approximately 0.5 pM / kg / min to approximately 35 pM / kg / min (e.g., approximately 3 pM / kg / min to approximately 17.5 pM / kg / min). For example, neuroprotective polypeptides (one or more types) are present at approximately 0.5 pM / kg / min to 35 pM / kg / min, approximately 0.5 pM / kg / min to 35 pM / kg / min, approximately 0.5 pM / kg / min to 32.5 pM / kg / min, approximately 0.5 pM / kg / min to 30 pM / kg / min, approximately 0.5 pM / kg / min to 27.5 pM / kg / min, approximately 0.5 pM / kg / min to 25 pM / kg / min, approximately 0.5 pM / kg / min to 22.5 pM / kg / min, and approximately 0.5 pM / kg / min to 20 pM / kg / min, about 0.5pM / kg / min to about 17.5pM / kg / min, about 0.5pM / kg / min to about 15pM / kg / min, about 0.5pM / kg / min to about 12.5pM / kg / min, about 0.5pM / kg / min to about 10pM / kg / min, about 1.5pM / kg / min to approx. 35pM / kg / min, approx. 1.5pM / kg / min to approx. 35pM / kg / min, approx. 1.5pM / kg / min to approx. 32.5pM / kg / min, approx. 1.5pM / kg / min to approx. 30pM / kg / min, approx. 1.5pM / kg / min to approx. 27.5pM / kg / min , about 1.5 pM / kg / min to about 25 pM / kg / min, about 1.5 pM / kg / min to about 22.5 pM / kg / min, about 1.5 pM / kg / min to about 20 pM / kg / min, about 1.5 pM / kg / min to about 17.5 pM / kg / min, about 1.5 pM / kg / min ~15pM / kg / min, approx. 1.5pM / kg / min ~ approx. 12.5pM / kg / min, approx. 1.5pM / kg / min ~ approx. 10pM / kg / min, approx. 2.5pM / kg / min ~ approx. 35pM / kg / min, approx. 2.5pM / kg / min ~ approx. 35pM / kg / min, approx. 2. 5pM / kg / min to about 32.5pM / kg / min, about 2.5pM / kg / min to about 30pM / kg / min, about 2.5pM / kg / min to about 27.5pM / kg / min, about 2.5pM / kg / min to about 25pM / kg / min, about 2.5pM / kg / min to about 22 .5pM / kg / min, about 2.5pM / kg / min to about 20pM / kg / min, about 2.5pM / kg / min to about 17.5pM / kg / min, about 2.5pM / kg / min to about 15pM / kg / min, about 2.5pM / kg / min to about 12.5pM / kg / min, about 2.5pM / kg / min to approx. 10pM / kg / min, approx. 5pM / kg / min to approx. 35pM / kg / min, approx. 5pM / kg / min to approx. 35pM / kg / min, approx. 5pM / kg / min to approx. 32.5pM / kg / min, approx. 5pM / kg / min min ~ approx. 30pM / kg / min, approx. 5pM / kg / min ~ approx. 27.5pM / kg / min, approx. 5pM / kg / min ~ approx. 25pM / kg / min, approx. 5pM / kg / min ~ approx. 22.5pM / kg / min, approx. 5pM / kg / min ~ approx. 20p M / kg / min, about 5pM / kg / min to about 17.5pM / kg / min, about 5pM / kg / min to about 15pM / kg / min, about 5pM / kg / min to about 12.5pM / kg / min, about 5pM / kg / min to about 10pM / kg / min , about 10 pM / kg / min to about 35 pM / kg / min, about 10 pM / kg / min to about 35 pM / kg / min, about 10 pM / kg / min to about 32.5 pM / kg / min, about 10 pM / kg / min to about 30 pM / kg / min, about 10 pM / kg / min to approx. 27.5pM / kg / min, approx. 10pM / kg / min to approx. 25pM / kg / min, approx. 10pM / kg / min to approx. 22.5pM / kg / min, approx. 10pM / kg / min to approx. 20pM / kg / min, approx. 10p M / kg / min to approx. 17.5 pM / kg / min, approx. 15 pM / kg / min to approx. 35 pM / kg / min, approx. 15 pM / kg / min to approx. 35 pM / kg / min, approx. 15 pM / kg / min to approx. 32.5 pM / kg / min, approx. It may be administered at a rate of approximately kg / min to 30 pM / kg / min, approximately 15 pM / kg / min to 27.5 pM / kg / min, approximately 15 pM / kg / min to 25 pM / kg / min, approximately 20 pM / kg / min to 35 pM / kg / min, approximately 20 pM / kg / min to 35 pM / kg / min, approximately 20 pM / kg / min to 32.5 pM / kg / min, approximately 20 pM / kg / min to 30 pM / kg / min, or approximately 25 pM / kg / min to 35 pM / kg / min.
[0085] In any aspect or embodiment described herein, a controlled-release preparation or (one or more) neuroprotective polypeptides may be administered by a device. For example, the device may be an implantable device that contains and delivers the controlled-release preparation or (one or more) neuroprotective polypeptides. The device may be a pump, minipump, osmotic pump, osmotic delivery device, infusion pump, intravenous administration device, peristaltic pump, or miniature infusion pump, etc. In any aspect or embodiment described herein, the device may be an implantable device that can deliver the controlled-release preparation or (one or more) neuroprotective polypeptides at a constant flow rate, an adjustable flow rate, or a programmable flow rate. For example, there are osmotic delivery devices such as those described in U.S. Patent No. 8,298,561 B2 or U.S. Patent No. 8,940,316 B2, both of which are incorporated herein by reference in their entirety.
[0086] As used herein, the term “osmotic delivery device” refers to a device used for the delivery of one or more beneficial agents (e.g., one or more neuroprotective polypeptides or controlled-release preparations) to a target, the device comprising, for example, a container (e.g., made of titanium alloy) containing a suspension preparation (e.g., one or more neuroprotective polypeptides or controlled-release preparations) in an internal cavity, and the osmotic agent preparation. A piston assembly located within the internal cavity separates the osmotic agent preparation from the suspension preparation. A semipermeable membrane is positioned at the first distal end of the container adjacent to the osmotic agent preparation, and a flow regulator is positioned at the second distal end of the container adjacent to the suspension preparation (the flow regulator defines a delivery port through which the suspension preparation is released from the device). The osmotic delivery device or osmotic pump may be implanted in the subject's body, for example, subcutaneously (for example, in the inner, outer, or posterior part of the upper arm, or in the abdominal region).
[0087] The neuroprotective polypeptides or controlled-release preparations described herein (one or more) may, when administered by a device, provide sustained delivery of the neuroprotective polypeptides or controlled-release preparations over a long period, such as several weeks, several months, or up to approximately one year. This device may be an implantable device capable of delivering the neuroprotective polypeptides or controlled-release preparations at a desired flow rate for a desired duration. The introduction of the neuroprotective polypeptides or controlled-release preparations into this implantable drug delivery device may be carried out by conventional techniques.
[0088] The neuroprotective polypeptides or controlled-release preparations (one or more) may be delivered, for example, using osmotically, mechanically, electromechanically, or chemically driven devices. In any aspect or embodiment described herein, the neuroprotective polypeptides or controlled-release preparations (one or more) are delivered at a flow rate that is therapeutically effective to the subject requiring treatment with the neuroprotective polypeptides (one or more).
[0089] The neuroprotective polypeptides or controlled-release preparations (one or more) may be delivered over a period ranging from about one week to about one year or more (for example, about one month to about one year or more, or about three months to about one year or more). The device may have a container having at least one pore through which the neuroprotective polypeptides or controlled-release preparations (one or more) are delivered. The neuroprotective polypeptides or controlled-release preparations (one or more) may be stored in the container. In any embodiment or aspect described herein, the device may be an implantable osmotic delivery device, and the delivery of the neuroprotective polypeptides or controlled-release preparations (one or more) is driven by osmosis. Several osmotic delivery devices or osmotic pumps and their components are described. Examples include DUROS® delivery devices or similar devices (for example, U.S. Patent Nos. 5,609,885, 5,728,396, 5,985,305, 5,997,527, 6,113,938, 6,132,420, 6,156,331, 6,217,906, 6,261,584, 6,270,787, 6,287,295, 6,375,978, 6,395,292, and 6,508,808). See Patent Nos. 6,544,252, 6,635,268, 6,682,522, 6,923,800, 6,939,556, 6,976,981, 6,997,922, 7,014,636, 7,207,982, 7,112,335, and 7,163,688, as well as U.S. Patent Applications Nos. 2005-0175701, 2007-0281024, and 2008-0091176, all of which are incorporated herein by reference).
[0090] A DUROS® delivery device typically consists of an osmotic engine, a piston, and a cylindrical container housing a drug preparation. The container is sealed at one end with a rate-controlled permeable membrane and at the other end with a diffusion regulator, through which the drug preparation is released from the drug container. The piston separates the drug preparation from the osmotic engine. The piston contains a sealant to prevent water from the osmotic engine compartment from flowing into the drug container. The diffusion regulator is designed to prevent body fluids from flowing into the drug container through a pore along with the drug preparation (e.g., one or more neuroprotective polypeptides or controlled-release preparations).
[0091] The DUROS® device releases a therapeutic agent at a predetermined rate based on the principle of osmosis. When extracellular fluid flows directly into the salt engine within the DUROS® device through a semipermeable membrane, the salt engine expands, propelling a piston at a slow, constant delivery rate. The movement of the piston releases the drug preparation (e.g., one or more neuroprotective polypeptides or controlled-release preparations) through a pore or exit hole at a predetermined shear rate. In any aspect or embodiment of the present invention, the DUROS® device container is introduced with one or more neuroprotective polypeptides or controlled-release preparations, which the device can deliver to a target at a predetermined, therapeutically effective delivery rate over a long period (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months).
[0092] Any embedded device may be used in the implementation of this disclosure, and such embedded device may include a regulator-type embedded pump capable of supplying a compound at a constant flow rate, an adjustable flow rate, or a programmable flow rate.
[0093] The amount of neuroprotective polypeptides or controlled-release preparations (one or more) used in the delivery device according to this disclosure is the amount required to deliver a therapeutically effective amount of the agent to achieve the desired therapeutic outcome. In practice, this amount may vary depending on variable factors such as the type of agent, the delivery site, the severity of the condition, and the desired therapeutic effect. Typically, the volume of the beneficial agent chamber for containing the neuroprotective polypeptides or controlled-release preparations (one or more) in the osmotic delivery device is about 100 μl to about 1000 μl (e.g., about 120 μl and about 500 μl or about 150 μl and about 200 μl).
[0094] In any aspect or embodiment described herein, the osmotic delivery device is implanted in the body of the subject, for example, subcutaneously. The device may be inserted in one or both arms (for example, on the medial, lateral, or posterior side of the upper arm) or in the abdomen. For example, the device may be implanted subcutaneously in the abdomen, in the area below the ribs and above the beltline. For the purpose of providing multiple locations for the insertion of one or more osmotic delivery devices in the abdomen, the abdominal wall may be divided into four quarters as follows: the upper right quarter extending 5 to 8 centimeters below the right rib and approximately 5 to 8 centimeters to the right of the midline; the lower right quarter extending 5 to 8 centimeters above the beltline and 5 to 8 centimeters to the right of the midline; the upper left quarter extending 5 to 8 centimeters below the left rib and approximately 5 to 8 centimeters to the left of the midline; and the lower left quarter extending 5 to 8 centimeters above the beltline and 5 to 8 centimeters to the left of the midline. This provides multiple locations that can be used to embed one or more devices in one or more cases.
[0095] In other embodiments, administration of controlled-release neuroprotective preparations or provision of sustained delivery of neuroprotective polypeptides alleviates at least one symptom of at least one CNS-related condition selected from the group consisting of Parkinson's disease (PD), traumatic brain injury (TBI), multiple sclerosis, drug addiction, alcohol addiction, neurodegenerative states, brain inflammation, Alzheimer's disease (AD), multiple system atrophy, Huntington's disease, chronic traumatic encephalopathy, motor neuron diseases (e.g., amyotrophic lateral sclerosis, spinal cord injury, spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)), vascular dementia, Lewy body dementia (DLB), mixed dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, or combinations thereof.
[0096] In any embodiment or configuration described herein, administration of a controlled-release preparation or provision of sustained release of a neuroprotective polypeptide stabilizes the concentration of the neuroprotective polypeptide in plasma within a range of approximately 50 to approximately 4500 pg / mL.
[0097] In any embodiment or configuration described herein, administration of a controlled-release preparation or provision of sustained release of a neuroprotective polypeptide results in a cumulative increase in the concentration of the neuroprotective polypeptide in at least one of cerebrospinal fluid (CSF), the brain, or a combination thereof.
[0098] Neuroprotective polypeptides A neuroprotective polypeptide may contain amino acids selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 55. A neuroprotective polypeptide may contain an amino acid sequence selected from SEQ ID NOs: 1 to 55. Furthermore, the neuroprotective polypeptide may consist of an amino acid sequence selected from SEQ ID NOs. 1 to 55.
[0099] "GLP-1 or / or exendin-4 analogues" means modified GLP-1 and / or exendin amino acid sequences that exhibit agonist properties (i.e., exhibit one or more biological activities of GLP-1 or exendin-4). Such modifications include chimeric polypeptides containing one or more amino acid residues present in GLP-1 and one or more amino acid residues present in exendin-4. The above modifications also include truncations of either GLP-1 or exendin-4 or their chimeric polypeptides. For example, a truncated chimeric polypeptide is exendin-4 7-36 in which the G at position 36 is replaced with the R at position 36 of GLP-1. Polypeptides according to this disclosure include additions (i.e., insertions or additions), deletions, or substitutions of one or more amino acids in the amino acid sequence of GLP-1 or exendin-4 to such an extent that the functional activity is not significantly reduced compared to GLP-1 or exendin-4. For example, a deletion may be the deletion of an amino acid that is not essential for conferring differentiation-inducing activity as defined in the present invention, and a substitution may be conservative (i.e., substituting a basic, hydrophilic, or hydrophobic amino acid with an amino acid having the same properties) or non-conservative. A conservative substitution is a substitution in which the structural or chemical properties of the substituted amino acid are similar to those of the corresponding amino acid in the reference sequence.For example, conservative amino acid substitutions involve replacing one aliphatic or hydrophobic amino acid, such as alanine, valine, leucine, and isoleucine, with another aliphatic or hydrophobic amino acid; replacing one hydroxyl-containing amino acid, such as serine and threonine, with another hydroxyl-containing amino acid; replacing one acidic residue, such as glutamic acid or aspartic acid, with another acidic residue; replacing one amide-containing residue, such as asparagine and glutamine, with another amide-containing residue; replacing one aromatic residue, such as phenylalanine and tyrosine, with another aromatic residue; replacing one basic residue, such as lysine, arginine, and histidine, with another basic residue; and replacing one small amino acid, such as alanine, serine, threonine, methionine, and glycine, with another small amino acid. Therefore, if it is desirable to modify and alter the amino acid sequences of GLP-1 and exendinine-4, they may be modified and altered, and it is understood that in such cases, proteins with similar characteristics can be obtained. The amino acid sequence of GLP-1 or the exendin-4 amino acid sequence (or the nucleic acid sequence from which it is derived) may be modified in various ways, to the extent that it does not significantly reduce the biological utility or activity, and preferably increases such utility or activity.
[0100] In this specification, the terms “fragment” or “truncation” as used with respect to GLP-1, exendin-4, or polypeptides having amino acid sequences substantially homologous thereto, mean a polypeptide sequence consisting of at least five consecutive amino acids, which is present in any of GLP-1, exendin-4, or polypeptides having amino acid sequences substantially homologous thereto, and which polypeptide sequence has insulin secretion function.
[0101] Other modifications include D-enantiomers, in which at least one naturally occurring L-configuration of an amino acid residue is replaced with the D-configuration of that amino acid residue.
[0102] This disclosure intends to describe the use of spacers, such as lateral spacers. The term "lateral spacer" is defined as a compound incorporated into an amino acid sequence by chemical bonding. This compound increases the distance between two or more amino acid residues, thereby making the amino acid sequence less susceptible to cleavage (e.g., cleavage by DPP 1V) at or near the position in which the compound is incorporated, or preventing cleavage altogether. For example, the sequence AXB, having amino acid residues A and B and a lateral spacer X, is less susceptible to or not cleaved by enzymes compared to a sequence (AB) without a lateral spacer. For example, one to four compounds may be incorporated into an amino acid sequence as lateral spacers. Thus, in various embodiments, one, two, three, or four compounds may be inserted.
[0103] Generally, the lateral spacer is any compound capable of forming a peptide bond with an amino acid. That is, it contains at least one amino group and at least one carboxyl group (CO2), and this carboxyl group may be a carboxylic acid or its ester or salt. In one embodiment, the lateral spacer is of the formula H2N-R 1 -CO2H(I) is present in the formula, where R 1 This includes substituted or unsubstituted, branched or linear, C1-C20 alkyl, alkenyl, or alkynyl groups, or substituted or unsubstituted C3-C8 cycloalkyl groups, or substituted or unsubstituted C6-C20 aryl groups, or substituted or unsubstituted C4-C20 heteroaryl groups. In another embodiment, R 1 is equation (CH2) n It can be expressed as follows, where n is between 1 and 10. In one embodiment, R 1 This is (CH2)3(3-aminopropionic acid) or (CH2)5(6-aminohexanoic acid).
[0104] The present disclosure provides a method comprising administration of a controlled release preparation comprising at least one neuroprotective polypeptide. The polypeptide is a modified GLP-1 or exendin (e.g., exendin-4) sequence, or an analog or derivative thereof, in which a spacer is disposed between amino acid residues corresponding to the 7th and 8th residues of GLP-1 (e.g., in the case of GLP-1 with an Aha spacer, referred to as "GLP-1 Aha 8 "), or in which a spacer is disposed between amino acid residues corresponding to the 8th and 9th residues of GLP-1 (e.g., in the case of GLP-1 with an Aha spacer, referred to as "GLP-1Aha 9 "). The lateral spacer is, in one embodiment, one or more aminopropionic acid residues. In one embodiment, the spacer is a 6-aminohexanoic acid spacer, and this 6-aminohexanoic acid spacer contains less than 4 6-aminohexanoic acid residues. The polypeptide may, for example, be one in which one or more 6-aminohexanoic acid residues are included between the 7th and 8th residues of GLP-1 7-36 (i.e., GLP-1 Aha 8 ), or may include one in which one or more 6-aminohexanoic acid residues are included between the 8th and 9th residues of GLP-1 7-36. The polypeptide may be one in which two or more 6-aminohexanoic acid residues are included between the 7th and 8th residues of GLP-1 7-36 (i.e., GLP-1 Aha 8 ), or may include one in which two or more 6-aminohexanoic acid residues are included between the 8th and 9th residues of GLP-1 7-36. The polypeptide may, for example, be one in which three or more 6-aminohexanoic acid residues are included between the 7th and 8th residues of GLP-1 7-36 (i.e., GLP-1 Aha 8 ), or may include one in which three or more 6-aminohexanoic acid residues are included between the 8th and 9th residues of GLP-1 7-36.
[0105] In other embodiments, the polypeptides of the Disclosure have an insulin secretion effect equivalent to that of an equimolar amount of GLP-1, or, in one embodiment, an insulin secretion effect equivalent to that of an equimolar amount of exendin-4. "Equivalent effect" means an effect of about 10-15% of the effect of GLP-1 or exendin-4. In another embodiment, the polypeptide has an insulin secretion effect greater than that of either GLP-1 or exendin-4. "Greater than the effect" of GLP-1 or exendin-4 means that the insulin secretion effect is increased compared to GLP-1 or exendin-4, for example, the magnitude of the increase is greater than about 10% of the effect of GLP-1 or exendin-4. Thus, in one embodiment, the polypeptides of the Disclosure have a similar potency to GLP-1 or exendin-4, and in another embodiment, the polypeptides of the Disclosure have a higher potency than GLP-1 and optionally a higher potency than exendin-4. In other embodiments, the polypeptides of the Disclosure have a longer-lasting effect than GLP-1. In a further embodiment, the polypeptide has a longer-lasting effect at least comparable to that of exendin-4. In other embodiments, the polypeptide has a longer-lasting effect than exendin-4. "Longer-lasting effect than" means that the polypeptide is more resistant to at least one degrading enzyme than GLP-1 or exendin-4. For example, the polypeptides of the Disclosure are more resistant to degradation by the enzyme dipeptidyl peptidase-4 (DPPIV) than GLP-1, and optionally more resistant than exendin-4. Such resistance to one or more degrading enzymes can be directly investigated by detecting the amount of degradation products (e.g., the amount of the N-terminal degradation product) or the amount of uncleaved polypeptide. Alternatively, such resistance to one or more degrading enzymes may be indirectly detected by examining the decrease in insulin secretion over time after administration of the polypeptides of the Disclosure. For example, as the polypeptides of the Disclosure are cleaved by degrading enzymes, plasma insulin levels will decrease after a single administration.In additional embodiments, the rate of this decline is thought to be slower than that of GLP-1 and / or possibly even slower than that of exendine-4.
[0106] The polypeptides relating to this disclosure may be prepared by any of several chemical polypeptide synthesis techniques, such as solution methods and solid-phase methods, which are widely known to those with ordinary skill in the art. Solid-phase synthesis involves attaching the C-terminal amino acid of a polypeptide sequence to an insoluble carrier, followed by the sequential addition of the remaining amino acids of the sequence. This method is one of the synthesis methods for preparing polypeptides. Solid-phase synthesis techniques are described by Merrifield et al., J.Am.Chem.Soc.85:2149-2156 (1963). Many automated systems for performing solid-phase peptide synthesis are commercially available.
[0107] Solid-phase synthesis is carried out by starting from the carboxyl terminus (i.e., the C-terminus) of a polypeptide and coupling the protected amino acid to a suitable solid carrier via its carboxyl group. The solid carrier used is not particularly important as long as it can bind to the carboxyl group and is substantially inert to the reagents used in the peptide synthesis procedure. For example, starting materials may be prepared by attaching amino acid groups protected via benzyl ester bonds to chloromethylated or hydroxymethyl resins, or by attaching them via amide bonds to benzhydrylamine (BHA) resins or p-methylbenzhydrylamine (MBHA) resins. Suitable materials for use as solid carriers are widely known to those skilled in the art and include, but are not limited to, halomethyl resins such as chloromethyl or bromomethyl resins, hydroxymethyl resins, phenolic resins such as 4-(a-[2,4-dimethoxyphenyl]-Fmoc-aminomethyl)phenoxy resins, and tert-alkyloxycarbonylhydrazide resins. Such resins are commercially available, and their preparation methods are well known to those with ordinary skill in the art.
[0108] The acid form of the peptide may be prepared by a solid-phase peptide synthesis procedure using a benzyl ester resin as the solid carrier. The corresponding amide may be produced by using a benzhydrylamine or methylbenzhydrylamine resin as the solid carrier. Those skilled in the art will recognize that, when using a BHA or MBHA resin, cleaving the peptide from the solid carrier by treatment with hydrofluoric anhydride will produce a peptide having a terminal amide group.
[0109] The α-amino group of each amino acid used in synthesis should be protected to prevent side reactions involving reactive α-amino functional groups during the coupling reaction. For amino acids further containing reactive side-chain functional groups (e.g., sulfhydryl, amino, carboxy, hydroxy, etc.), they must be protected with an appropriate protecting group to prevent chemical reactions at that site from occurring during peptide synthesis. Protecting groups are widely known to those skilled in the art. See, for example, *The Peptides: Analysis, Synthesis, Biology, Vol. 3: Protection of Functional Groups in Peptide Synthesis* (Gross and Meienhofer (eds.), Academic Press, NY (1981)).
[0110] If the α-amino protecting group is appropriately selected, it can inactivate the α-amino functional group during the coupling reaction, and after coupling, it can be easily removed under conditions that do not result in the removal of the side chain protecting group, thereby preserving the structure of the peptide fragment without alteration, and preventing racemization due to activation immediately before coupling. Similarly, the side chain protecting group must be selected to inactivate the side chain functional group during synthesis, be stable under the conditions for removing the α-amino protecting group, and be removable after the completion of peptide synthesis under conditions that do not alter the structure of the peptide.
[0111] Amino acid coupling may be carried out by various techniques well known to those skilled in the art. Typical methods involve converting amino acids into derivatives to facilitate the reaction between their carboxyl group and the free N-terminal amino group of the peptide fragment, or by using suitable coupling agents such as N,N'-dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIPCDI). In many cases, hydroxybenzotriazole (HOBt) is used as a catalyst for these coupling reactions.
[0112] Generally, peptide synthesis begins by coupling a C-terminal amino acid, whose N-amino position is protected by a protecting group such as fluorenylmethyloxycarbonyl (Fmoc), to a solid carrier. Before coupling Fmoc-Asn, it is necessary to cleave the Fmoc residue from the polymer. For example, Fmoc-Asn can be coupled to a 4-(a-[2,4-dimethoxyphenyl]-Fmoc-amino-methyl)phenoxy resin using N,N'-dicyclohexylcarbodiimide (DCC) and hydroxybenzotriazole (HOBt) at approximately 25°C for approximately 2 hours with stirring. After coupling the Fmoc-protected amino acid to the resin carrier, the α-amino protecting group is removed at room temperature using DMF containing 20% piperidine.
[0113] After the removal of the α-amino protecting group, the remaining Fmoc-protected amino acids are coupled stepwise in the desired order. Appropriately protected amino acids are commercially available from several suppliers (e.g., Novartis (Switzerland) or Bachem (Torrance, CA)). Instead of adding amino acids stepwise, a well-protected peptide fragment consisting of more than one amino acid may be coupled to the "elongating" peptide. The selection of appropriate coupling reagents is widely known to those skilled in the art, as described above.
[0114] Each of the protected amino acids or amino acid sequences is introduced in excess into a solid-phase reactor, and coupling is carried out using dimethylformamide (DMF), methylene chloride (CH2Cl2), or a mixture thereof as the medium. If the coupling is incomplete, the coupling reaction may be repeated until the N-amino group is deprotected and the next amino acid is added. The coupling efficiency may be monitored by several means widely known to those skilled in the art. The method for monitoring the coupling efficiency may be a ninhydrin reaction. The peptide synthesis reaction may be carried out automatically using several commercially available peptide synthesizers, such as the Biosearch 9500® synthesizer (Biosearch, San Raphael, CA).
[0115] The peptide may be cleaved, and the protecting group may be removed by stirring an insoluble carrier or solid carrier in anhydrous liquid hydrogen fluoride (HF) in the presence of anisole and dimethyl sulfide at approximately 0°C for about 20 to about 90 minutes, for example, 60 minutes; or, depending on the selected protecting group, by continuously aerating a suspension of 1 mg / 10 mL of resin suspended in trifluoroacetic acid (TFA) with hydrogen bromide (HBr) for 60 to 360 minutes at approximately room temperature; or by incubating the solid carrier in the reaction column used for solid-phase synthesis with 90% trifluoroacetic acid, 5% water and 5% triethylsilane for about 30 to about 60 minutes. Alternatively, other deprotection methods widely known to those skilled in the art may be used.
[0116] Peptides may be isolated and purified from the reaction mixture by peptide purification methods widely known to those skilled in the art. For example, peptides may be purified by well-known chromatographic methods such as reverse-phase HPLC, gel permeation, ion exchange, size exclusion, affinity, partition, or countercurrent partition.
[0117] Furthermore, the preparation of neuroprotective polypeptides may be carried out by other means, such as recombinant technology. For examples of appropriate cloning and sequencing techniques and sufficient explanation for those skilled in the art to conduct many cloning exercises, see Sambrook et al. (1989) Molecular Cloning - A Laboratory Manual (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY, (Sambrook).
[0118] For example, the exendin derivatives (one or more) used in the controlled-release preparation may be compounds represented by chemical formula I, or pharmaceutically acceptable salts thereof: Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala Xaa27 Xaa28 -Z1 (Chemical formula I) (In the formula, Xaa1 is His, Arg, Tyr, Ala, Norval, Val, Norleu, or 4-imidazopropionyl. Xaa2 is Ser, Gly, Ala, or Thr. Xaa3 is Ala, Asp, or Glu. Xaa4 is Ala, Norval, Val, Norleu, or Gly. Xaa5 is Ala or Thr, Xaa6 is Ala, Phe, Tyr, or naphthylalanine. Xaa7 is either Thr or Ser. Xaa8 is Ala, Ser, or Thr. Xaa9 is Ala, Norval, Val, Norleu, Asp, or Glu. Xaa10 is Ala, Leu, Ile, Val, pentylglycine, or Met. Xaa11 is either Ala or Ser. Xaa12 is either Ala or Lys. Xaa13 is Ala or Gln, Xaa14 is Ala, Leu, Ile, pentylglycine, Val, or Met. Xaa15 is either Ala or Glu. Xaa16 is either Ala or Glu. Xaa17 is either Ala or Glu. Xaa19 is either Ala or Val. Xaa20 is Ala or Arg. Xaa21 is Ala, Leu, or Lys-NHε-R, where R is Lys, Arg, or a linear or branched alkanoyl having 1 to 10 carbon atoms. Xaa22 is Ala, Phe, Tyr, or naphthylalanine. Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met. Xaa24 is Ala, Glu, or Asp. Xaa25 is Ala, Trp, Phe, Tyr, or naphthylalanine. Xaa26 is either Ala or Leu. Xaa27 is either Ala or Lys. Xaa28 is either Ala or Asn, and Z1 is -OH, -NH2, Gly-Z2, Gly Gly-Z2, Gly Gly Xaa31-Z2, Gly Gly Xaa31 Ser-Z2, Gly Gly Xaa31 Ser Ser-Z2, Gly Gly Xaa31 Ser Ser Gly-Z2, Gly Gly Xaa31 Ser Ser Gly Ala-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2, or Gly Gly Xaa31 Ser Ser Gly Ala Xaa31, Xaa36, Xaa37, and Xaa38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine, or N-alkylalanine, and Xaa39 is Ser or Tyr (for example, Ser), and Z2 is -OH or -NH2. however, Of Xaa3, Xaa4, Xaa5, Xaa6, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27, and Xaa28, no more than three are Ala, and If Xaa1 is His, Arg, or Tyr, then at least one of Xaa3, Xaa4, and Xaa9 is Ala.
[0119] In some embodiments, the N-alkyl groups of N-alkylglycine, N-alkylpentylglycine, and N-alkylalanine may include lower alkyl groups having, for example, 1 to about 6 carbon atoms or 1 to 4 carbon atoms. The compounds represented by chemical formula I may include the compounds shown in Examples 1 to 89 of PCT Application No. PCT / US98 / 24273 filed on November 13, 1998 (title of the invention, “Novel Exendin Agonist Compounds,” the entirety of which is incorporated herein by reference for all purposes) (compounds 1 to 89, respectively), as well as the compounds shown in corresponding Examples 104 and 105.
[0120] In one specific embodiment, the exenzine derivative of chemical formula I may include those in which Xaa1 of chemical formula I is His, Ala, Norval, or 4-imidazopropionyl. In another embodiment, Xaa1 of chemical formula I is His, Ala, or 4-imidazopropionyl. In an additional embodiment, Xaa1 of chemical formula I is His or 4-imidazopropionyl.
[0121] The exendin derivative of chemical formula I may be one in which Xaa2 is Gly. The exendin derivative of chemical formula I may be one in which Xaa3 is Ala.
[0122] The exendin derivative of chemical formula I may be one in which Xaa4 is Ala. The exendin derivative of chemical formula I may be one in which Xaa9 is Ala.
[0123] The exendine derivative of chemical formula I may be one in which Xaa14 is Leu, pentylglycine, or Met.
[0124] The exendine derivative of chemical formula I may be one in which Xaa21 is Lys-NHε-R, where R is Lys, Arg, or a linear or branched alkanoyl having 1 to 10 carbon atoms.
[0125] In one embodiment, the exendin derivative of chemical formula I may be such that Xaa25 is Trp or Phe.
[0126] In another embodiment, the exendin derivative of chemical formula I may be such that Xaa6 is Ala, Phe, or naphthylalanine, Xaa22 is Phe or naphthylalanine, and Xaa23 is Ile or Val. Furthermore, in the exendin derivative of chemical formula I, Xaa31, Xaa36, Xaa37, and Xaa38 are independently selected from the group consisting of Pro, homoproline, thioproline, and N-alkylalanine, Z1 may be -NH2, and Z2 may be -NH2.
[0127] In other embodiments, the exendin derivative of chemical formula I may be such that Xaa1 is Ala, His, or Tyr (for example, Ala or His), Xaa2 is Ala or Gly, Xaa6 is Phe or naphthylalanine, Xaa14 is Ala, Leu, pentylglycine, or Met, Xaa22 is Phe or naphthylalanine, Xaa23 is Ile or Val, Xaa31, Xaa36, Xaa37, and Xaa38 are independently selected from the group consisting of Pro, homoproline, thioproline, and N-alkylalanine, Xaa39 is Ser or Tyr (for example, Ser), and Z1 may be -NH2.
[0128] According to one embodiment, the exenzine derivative of chemical formula I is such that Xaa1 is His or Ala, Xaa2 is Gly or Ala, Xaa3 is Ala, Asp, or Glu, Xaa4 is Ala or Gly, Xaa5 is Ala or Thr, Xaa6 is Phe or naphthylalanine, Xaa7 is Thr or Ser, Xaa8 is Ala, Ser, or Thr, Xaa9 is Ala, Asp, or Glu, Xaa10 is Ala, Leu, or pentylglycine, Xaa11 is Ala or Ser, Xaa12 is Ala or Lys, Xaa13 is Ala or Gln, and Xaa14 is Ala, Leu, Met, Xaa15 is pentylglycine, Xaa15 is Ala or Glu, Xaa16 is Ala or Glu, Xaa17 is Ala or Glu, Xaa19 is Ala or Val, Xaa20 is Ala or Arg, Xaa21 is Ala or Leu, Xaa22 is Phe or naphthylalanine, Xaa23 is Ile, Val, or tert-butylglycine, Xaa24 is Ala, Glu, or Asp, Xaa25 is Ala, Trp, or Phe, Xaa26 is Ala or Leu, Xaa27 is Ala or Lys, Xaa28 is Ala or Asn, and Z1 is -OH, -NH2, Gly-Z2, Gly Gly-Z2, Gly Gly Xaa31-Z2, Gly Gly Xaa31 Ser-Z2, Gly Gly Xaa31 Ser Ser-Z2, Gly Gly Xaa31 Ser Ser Gly-Z2, Gly Gly Xaa31 Ser Ser Gly Ala-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2, or Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37Xaa39-Z2, where Xaa31, Xaa36, Xaa37, and Xaa38 are independently Pro, homoproline, thioproline, or N-methylalanine, where Xaa39 is Ser or Tyr (for example, Ser), and Z2 is -OH or -NH2, where Xaa3, Xaa5, Xaa6, Xaa8, Xaa10, Xaa11, Xaa12, If no more than three of Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27, and Xaa28 are Ala, and Xaa1 is His, Arg, or Tyr, then at least one of Xaa3, Xaa4, and Xaa9 may be Ala.
[0129] In further embodiments, the compound of chemical formula I may include those having the amino acid sequences of SEQ ID NOs. 5 to 93 as described in PCT application number PCT / US98 / 25728, or those described in U.S. Provisional Application No. 60 / 066,029 (these are incorporated herein by reference).
[0130] According to one embodiment, a compound is provided in which Xaa14 is Leu, Ile, Val, or pentylglycine (for example, Leu or pentylglycine) and Xaa25 is Ala, Phe, Tyr, or naphthylalanine (for example, Phe or naphthylalanine). These compounds will be resistant to oxidative degradation both in vitro and in vivo, and during the synthesis of the compounds.
[0131] In another embodiment, the exendin derivative may include the compound represented by chemical formula II, or a pharmaceutically acceptable salt thereof: Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala X1-Z1 (Chemical formula II) (In the formula, Xaa1 is His, Arg, Tyr, Ala, Norval, Val, Norleu, or 4-imidazopropionyl. Xaa2 is Ser, Gly, Ala, or Thr. Xaa3 is Ala, Asp, or Glu. Xaa4 is Ala, Norval, Val, Norleu, or Gly. Xaa5 is Ala or Thr, Xaa6 is Ala, Phe, Tyr, or naphthylalanine. Xaa7 is either Thr or Ser. Xaa8 is Ala, Ser, or Thr. Xaa9 is Ala, Norval, Val, Norleu, Asp, or Glu. Xaa10 is Ala, Leu, Ile, Val, pentylglycine, or Met. Xaa11 is either Ala or Ser. Xaa12 is either Ala or Lys. Xaa13 is Ala or Gln, Xaa14 is Ala, Leu, Ile, pentylglycine, Val, or Met. Xaa15 is either Ala or Glu. Xaa16 is either Ala or Glu. Xaa17 is either Ala or Glu. Xaa19 is either Ala or Val. Xaa20 is either Ala or Arg. Xaa21 is Ala, Leu, or Lys-NHε-R (where R is Lys, Arg, a linear or branched alkanoyl having 1 to 10 carbon atoms, or a cycloaleyl-alkanoyl), Xaa22 is Phe, Tyr, or naphthylalanine. Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met. Xaa24 is Ala, Glu, or Asp. Xaa25 is Ala, Trp, Phe, Tyr, or naphthylalanine. Xaa26 is either Ala or Leu. X1 is Lys Asn, Asn Lys, Lys-NHε-R Asn, Asn Lys-NHε-R, Lys-NHε-R Ala, Ala Lys-NHε-R, where R is Lys, Arg, a linear or branched alkanoyl having 1 to 10 carbon atoms, or a cycloalkyl alkanoyl. Z1 is -OH, -NH2, Gly-Z2, Gly Gly-Z2, Gly Gly Xaa31-Z2, Gly Gly Xaa31 Ser-Z2, Gly Gly Xaa31 Ser Ser-Z2, Gly Gly Xaa31 Ser Ser Gly-Z2, Gly Gly Xaa31 Ser Ser Gly Ala-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2, or Gly Gly Xaa31 Ser Ser Gly Ala Xaa31, Xaa36, Xaa37, and Xaa38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine, and N-alkylalanine, and Xaa39 is Ser or Tyr, and Z2 is -OH or -NH2), however, Of Xaa3, Xaa4, Xaa5, Xaa6, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, and Xaa26, no more than three are Ala, and If Xaa1 is His, Arg, Tyr, or 4-imidazopropionyl, then at least one of Xaa3, Xaa4, and Xaa9 is Ala.
[0132] In certain embodiments, the exendin derivative of chemical formula II may include those in which Xaa1 is His, Ala, Norval, or 4-imidazopropionyl (for example, those containing Xaa1 is His, 4-imidazopropionyl, or Ala, or those containing Xaa1 is His or 4-imidazopropionyl).
[0133] The exendin derivative of chemical formula II may be one in which Xaa2 is Gly. The exendin derivative of chemical formula II may be one in which Xaa4 is Ala.
[0134] The exendin derivative of chemical formula II may be one in which Xaa9 is Ala. The exendin derivative of chemical formula II may be one in which Xaa14 is Leu, pentylglycine, or Met.
[0135] The exendin derivative of chemical formula II may be one in which Xaa25 is Trp or Phe.
[0136] The exendin derivative of chemical formula II may be such that Xaa6 is Ala, Phe, or naphthylalanine, Xaa22 is Phe or naphthylalanine, and Xaa23 is Ile or Val.
[0137] The exendine derivative of chemical formula II may be one in which Z1 is -NH2. The exenzine derivative of chemical formula II may be such that Xaa31, Xaa36, Xaa37, and Xaa38 are independently selected from the group consisting of Pro, homoproline, thioproline, and N-alkylalanine.
[0138] Exendine derivatives of chemical formula II may have Xaa39 as Ser or Tyr (for example, Ser). Exendine derivatives of chemical formula II may have Z2 as -NH2.
[0139] The exendine derivative of chemical formula II may be one in which Z1 is -NH2. The exendine derivative of chemical formula II may be one in which Xaa21 is Lys-NHε-R, where R is Lys, Arg, or a linear or branched alkanoyl having 1 to 10 carbon atoms.
[0140] The exendin derivative of chemical formula II may be one in which X1 is Lys Asn, Lys-NHε-R Asn, or Lys-NHε-R Ala, where R is Lys, Arg, or a linear or branched alkanoyl having 1 to 10 carbon atoms.
[0141] In further embodiments, the exenzine derivative of chemical formula II may include compounds having the amino acid sequence shown by SEQ ID NOs. 95 to 110 as described in WO99 / 025728. The exenzine derivative of chemical formula II may include compounds having the amino acid sequence shown by SEQ ID NOs. 5 to 93 as described in PCT application PCT / US98 / 24210 (title of invention "Novel Exenzine Agonist Compounds") filed November 13, 1998. In another embodiment, the exenzine derivative of chemical formula II may include compounds having the amino acid sequence shown by SEQ ID NOs. 37 to 40 as described in WO99 / 007404. The above references are incorporated herein by reference.
[0142] The abbreviations used in chemical formulas I and II have the following meanings: "ACN" and "CH3CN" refer to acetonitrile.
[0143] "Boc," "tBoc," and "Tboc" refer to the t-butoxycarbonyl group. "DCC" refers to N,N'-dicyclohexylcarbodiimide.
[0144] "Fmoc" refers to fluorenyl methoxycarbonyl. "HBTU" refers to 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexafluorophosphate.
[0145] "HOBt" refers to 1-hydroxybenzotriazole monohydrate. "homoP" and "hPro" refer to homoproline.
[0146] "MeAla" and "Nme" refer to N-methylalanine. "Naph" refers to naphthylalanine.
[0147] "pG" and "pGly" refer to pentylglycine. "tBuG" refers to tert-butylglycine.
[0148] "ThioP" and "tPro" refer to thioproline. "3Hyp" refers to 3-hydroxyproline.
[0149] "4Hyp" refers to 4-hydroxyproline. "NAG" refers to N-alkylglycine.
[0150] "NAPG" refers to N-alkylpentylglycine. "Norval" refers to norvaline.
[0151] In one embodiment, the exendin fragment or derivative may have an amide group substituted or unsubstituted at its C-terminus, such as exendin-4(1-28) (SEQ ID NO: 15), exendin-4(1-28)amide, exendin-4(1-30) (SEQ ID NO: 7), exendin-4(1-30)amide, exendin-4(1-31) (SEQ ID NO: 54), exendin-4(1-31)amide, 14 Leu 25 Phe Exendin-4 (SEQ ID NO: 55), 14 Leu 25 Phe exendin-4 amide and pharmaceutically acceptable salts thereof may be selected from the group.
[0152] Controlled release preparation According to other embodiments, the controlled-release composition or microspheres may contain, as an active ingredient, exendin, GLP-1, or a therapeutically effective GLP-1 or exendin analog in an amount of about 0.1 to about 10 parts by weight (for example, about 0.8 to about 6 parts by weight) based on 100 parts by weight of the composition or microspheres comprising exendin (such as exendin-4), GLP-1, or a therapeutically effective GLP-1 or exendin analog (for example, an exendin-4 analog), a biodegradable polymer, and a coating material. For example, based on 100 parts by weight of a composition or microspheres comprising exendin or a therapeutically effective analog thereof and / or GLP-1 or a therapeutically effective analog thereof, exendin, GLP-1, or a therapeutically effective GLP-1 or exendin analog, a biodegradable polymer, and a coating material, the amount is approximately 0.1 to approximately 10 parts by weight, approximately 0.1 to approximately 9 parts by weight, approximately 0.1 to approximately 8 parts by weight, approximately 0.1 to approximately 7 parts by weight, approximately 0.1 to approximately 6 parts by weight, approximately 0.1 to approximately 6 parts by weight, approximately 0.1 to approximately 5 parts by weight, approximately 0.1 to approximately 4 parts by weight, approximately 0.1 to approximately 3 parts by weight, approximately 0.5 to approximately 10 parts by weight, approximately 0.5 to approximately 9 parts by weight, approximately 0.5 to approximately 8 parts by weight, approximately 0.5 to approximately 7 parts by weight, approximately 0.5 to approximately 6 parts by weight, approximately 0.5 to approximately 6 parts by weight, approximately 0.5 ~about 5 parts by weight, about 0.5 to about 4 parts by weight, about 0.5 to about 3 parts by weight, about 1 to about 10 parts by weight, about 1 to about 9 parts by weight, about 1 to about 8 parts by weight, about 1 to about 7 parts by weight, about 1 to about 6 parts by weight, about 1 to about 6 parts by weight , about 1 to about 5 parts by weight, about 1 to about 4 parts by weight, about 1 to about 3 parts by weight, about 2 to about 10 parts by weight, about 2 to about 9 parts by weight, about 2 to about 8 parts by weight, about 2 to about 7 parts by weight, about 2 to about 6 parts by weight, about 2 to about 6 parts by weight, It may contain approximately 2 to 5 parts by weight, approximately 2 to 4 parts by weight, approximately 3 to 10 parts by weight, approximately 3 to 9 parts by weight, approximately 3 to 8 parts by weight, approximately 3 to 7 parts by weight, approximately 3 to 6 parts by weight, approximately 4 to 10 parts by weight, approximately 4 to 9 parts by weight, approximately 4 to 8 parts by weight, approximately 4 to 7 parts by weight, approximately 5 to 10 parts by weight, approximately 5 to 9 parts by weight, approximately 5 to 8 parts by weight, approximately 6 to 10 parts by weight, approximately 6 to 9 parts by weight, or approximately 7 to 10 parts by weight.If the amount of exendin, GLP-1, or therapeutically effective GLP-1 or exendin analog contained in the composition or microspheres relating to this disclosure is less than the above range, the high efficacy of exendin, GLP-1, or therapeutically effective GLP-1 or exendin analog cannot be obtained. Furthermore, if the amount of exendin, GLP-1, or therapeutically effective GLP-1 or exendin analog is greater than the above range, the initial burst of exendin, GLP-1, or therapeutically effective GLP-1 or exendin analog increases, resulting in side effects caused by the initial burst. Therefore, it is preferable that the amount of exendin, GLP-1, or therapeutically effective GLP-1 or exendin analog be within the above range.
[0153] Biodegradable polymers refer to all polymers that are not harmful to humans, because when administered into the body, they can be slowly broken down and excreted. Biodegradable polymers may include one or more polymers selected from the group consisting of polylactides (PLA), polyglycolides (PGA), poly(lactide-co-glycolides) (PLGA), polyorthoesters, polyacid anhydrides, polyhydroxybutyric acid, polycaprolactone, and polyalkyl carbonates, as well as copolymers of one or more polymers with polyethylene glycol (PEG) (e.g., 1, 2, 3, 4, 5, 6, or more). The one or more polymers may be in the form of copolymers or simple mixtures.
[0154] For example, biodegradable polymers include poly(lactide-co-glycolide) (PLGA) such as RG502H (IV=0.16-0.24 dL / g), RG503H (IV=0.32-0.44 dL / g), and RG504H (IV=0.45-0.60 dL / g) with a lactide:glycolide ratio of 1:1, and RG752H (IV=0.14-0.22 dL / g) with a lactide:glycolide ratio of 75:25, as well as polylactide (PLA) such as R202H (IV=0.16-0.24 dL / g) and R203H (IV=0.25-0.35 dL / g) (all supplied by Evnik, Germany), and 5050DL with a lactide:glycolide ratio of 1:1. It may be one or more polymers selected from the group consisting of poly(lactide-co-glycolide) copolymers (copolymers provided by Evonik (Parsippany, NJ, USA)) such as 2A (IV=0.15–0.25 dL / g), 5050DL 3A (IV=0.25–0.43 dL / g), and 5050DL 4A (IV=0.38–0.48 dL / g), but equivalent polymers may be provided or obtained from any suitable supplier.
[0155] In further embodiments, the biodegradable polymer may be a polymer-sugar complex. This polymer-sugar complex is formed by coupling a sugar with (1) a polymer selected from the group consisting of polylactide (PLA), polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), polyorthoester, polyacid anhydride, polyhydroxybutyric acid, polycaprolactone, and polyalkyl carbonate, (2) a copolymer consisting of at least two of the above polymer group, or (3) a copolymer of polyethylene glycol (PEG) and one of the above polymer group.
[0156] In other embodiments of this disclosure, the polymer-sugar complex may refer to a complex in which the hydroxyl groups of a sugar are substituted with polymers. The sugar may include monosaccharides and polysaccharides having 1 to 8 unit sugars (each unit sugar having 3 to 6 hydroxyl groups) and linear sugar alcohols having 3 to 6 hydroxyl groups and a molecular weight of 20,000 or less. This sugar alcohol may include mannitol, pentaerythritol, sorbitol, ribitol, and xylitol. The polymer and sugar are coupled at three or more hydroxyl groups of the sugar.
[0157] The polymer-sugar complex according to the above embodiment may be suitable as a biodegradable polymer because it has in vivo properties similar to those of the polymer coupled with the sugar, has various degradation rates depending on the type of polymer used, and is broken down into harmless polymers and sugars in the body. In one embodiment, the polymer-sugar complex may be a PLA-glucose complex, a PGA-glucose complex, or a PLGA-glucose complex, and this PLGA-glucose complex may have the following structure.
[0158] [Formula 1]
[0159] In the controlled-release microspheres according to this disclosure, the coating layer formed on their surface can effectively control the initial burst of exendin or GLP-1 or a therapeutically effective GLP-1 or exendin analog, thereby preventing side effects caused by excessive initial bursts. Biodegradable polymers may be used without viscosity restrictions.
[0160] In the controlled-release compositions / preparations of this disclosure, the biodegradable polymer serves as a matrix protecting the active ingredient (exendine, GLP-1, or a therapeutically effective GLP-1 or exendine analog). Therefore, if the viscosity of the polymer is not sufficiently low, the active ingredient cannot be effectively protected, resulting in increased initial burst. If the viscosity of the polymer is too high, the total amount of active ingredient released decreases, resulting in reduced bioavailability. In this disclosure, not only the biodegradable polymer but also the coating material contained in the composition plays a role in controlling drug release, and therefore, a relatively low-viscosity biodegradable polymer can be used. Accordingly, in order to effectively control the initial burst of the drug and improve bioavailability, the intrinsic viscosity (IV) of the biodegradable polymer may be about 0.1 to about 0.6 dL / g (e.g., about 0.15 to about 0.31 dL / g or about 0.16 to about 0.24 dL / g). The intrinsic viscosity is measured using an Ubbelohde viscometer at 25°C ± 0.1°C with a biodegradable polymer dissolved in chloroform at a concentration of 1% (W / V).
[0161] In the compositions, preparations, or microspheres relating to this disclosure, the biodegradable polymer serves as a matrix for protecting the active ingredient and controlling the release rate during release, and its content in the composition or microsphere may be about 85 to about 99.89 parts by weight (for example, about 91 to about 99 parts by weight) based on 100 parts by weight of the composition / preparation or microsphere comprising the active ingredient (exendine, GLP-1, or a therapeutically effective GLP-1 or exendine analog), the biodegradable polymer, and the coating material.
[0162] The coating material is used to prevent excessive initial bursting and increase the bioavailability of the active ingredient, and in the microspheres according to this disclosure, the coating material may be in the form of a coating layer formed on the surface of the microspheres. The coating material may be one or more (e.g., 1, 2, or 3) selected from basic amino acids, polypeptides, and organic nitrogen compounds. The basic amino acids may include arginine, lysine, histidine, and their derivatives. The polypeptide may contain 2 to 10 amino acids (e.g., 2 to 5 amino acids) including one or more (e.g., 1, 2, or 3) selected from arginine, lysine, and histidine. The polypeptide may contain more basic amino acids than acidic amino acids and therefore may exhibit basicity. For example, the polypeptide may be L-Ala-L-His-L-Lys, L-Arg-L-Phe, Gly-L-His, Gly-L-His-Gly, Gly-L-His-L-Lys, L-His-Gly, L-His-Leu, L-Lys-L-Tyr-L-Lys, L-His-L-Val, L-Lys-L-Lys, L-Lys-L-Lys-L-Lys, and L-Lys-L-Thr-L-Thr-L-Lys-L-Ser. Furthermore, the above organic nitrogen compound may be creatine, creatinine, and urea.
[0163] The amount of coating material contained in or coating the microspheres in the composition relating to this disclosure is about 0.01 to about 5 parts by weight (for example, about 0.015 to about 3 parts by weight, about 0.01 to about 4, about 0.01 to about 3, about 0.01 to about 3, about 0.01 to about 2, about 0.01 to about 4, about 0.01 to about 4) based on 100 parts by weight of the composition or microspheres comprising exendin, GLP-1, or a therapeutically effective GLP-1 or exendin analog, a biodegradable polymer, and the coating material. 5, approximately 0.015 to approximately 4, approximately 0.015 to approximately 2, approximately 0.05 to approximately 5, approximately 0.05 to approximately 4, approximately 0.05 to approximately 3, approximately 0.05 to approximately 2, approximately 0.1 to approximately 5, approximately 0.1 to approximately 4, approximately 0.1 to approximately 3, approximately 0.1 to approximately 2, approximately 0.5 to approximately 5, approximately 0.05 to approximately 4, approximately 0.05 to approximately 3, approximately 0.05 to approximately 2, approximately 1 to approximately 5, approximately 1 to approximately 4, approximately 1 to approximately 3, approximately 1.5 to approximately 5, approximately 1.5 to approximately 4, approximately 1.5 to approximately 3, approximately 2 to approximately 5, approximately 2 to approximately 4, approximately 3 to approximately 5, approximately 3 to approximately 4, or approximately 4 to approximately 5). If the content of the coating material is less than the above range, drug release cannot be effectively controlled, and if the content of the coating material is more than the above range, a further increase in the initial burst control effect cannot be obtained.
[0164] Each controlled-release microsphere according to the present disclosure may have a smooth surface covered with a coating material and have an average size of about 1 to about 50 μm (for example, about 5 to about 30 μm, about 1 to about 40 μm, about 1 to about 30 μm, about 1 to about 20 μm, about 1 to about 10 μm, about 5 to about 50 μm, about 5 to about 40 μm, about 5 to about 30 μm, about 5 to about 20 μm, about 5 to about 10 μm, about 10 to about 50 μm, about 10 to about 40 μm, about 10 to about 30 μm, about 10 to about 20 μm, about 20 to about 50 μm, about 20 to about 40 μm, about 20 to about 30 μm, about 30 to about 50 μm, about 30 to about 40 μm, or about 40 to about 50 μm). The smooth surface of the microspheres effectively controls the initial burst, resulting in excellent bioavailability.
[0165] Unlike conventional forms, controlled-release microspheres, or microspheres prepared from the compositions / preparations of this disclosure, are coated with a coating material, thereby achieving prevention of excessive / harmful initial bursts and increased bioavailability, which is not achievable with conventional microspheres containing exendin, GLP-1, or therapeutically effective GLP-1 or exendin analogs. In particular, it is very important to reduce the initial burst amount to 5% or less, as excessive / harmful initial bursts of exendin, GLP-1, or therapeutically effective GLP-1 or exendin analogs cause various side effects such as vomiting, nausea, and headache. Controlled-release microspheres, or microspheres prepared from the compositions (or preparations) of this disclosure, reduce the initial 24-hour release to 5% or less. To reduce side effects resulting from the administration of controlled-release microspheres containing exendin, GLP-1, or therapeutically effective GLP-1 or exendin analogs, the initial burst volume in the first hour may be approximately 5% or less (e.g., approximately 4% or less, approximately 3% or less, approximately 2% or less, or approximately 1% or less). Since the microspheres according to this disclosure include a coating layer of coating material on their surface, the initial burst is effectively controlled, preventing side effects caused by excessive / harmful initial bursts, and resulting in excellent bioavailability due to the sustained and sufficient release of the drug.
[0166] In one embodiment of the present disclosure, the preparation or microspheres may further contain excipients such as protective colloids and / or stabilizers.
[0167] The composition or microspheres may further contain one or more protective colloids selected from polyvinyl alcohol, albumin, polyvinylpyrrolidone, and gelatin. The protective colloids do not have any special effect in preventing excessive / harmful initial bursts of the active ingredients contained in the microspheres, but they play a role in preventing aggregation of the microspheres and improving dispersibility. Considering these roles, the protective colloid content is approximately 0.02% (W / W) to approximately 1.0% (W / W) (for example, approximately 0.02% to approximately 0.8%, approximately 0.02% to approximately 0.6%, approximately 0.02% to approximately 0.4%, approximately 0.05% to approximately 1.0%, approximately 0.04% to approximately 0.8%, approximately 0.05% to approximately 0.5%, approximately 0.05% to approximately 0.0) based on the weight of the composition, preparation, or microspheres, including exendin, GLP-1, or a therapeutically effective GLP-1 or exendin analog, a biodegradable polymer, and a coating material. It may be 0.4%, approximately 0.05% to approximately 0.3%, approximately 0.05% to approximately 0.2%, approximately 0.1% to approximately 1.0%, approximately 0.1% to approximately 0.8%, approximately 0.1% to approximately 0.6%, approximately 0.1% to approximately 0.4%, approximately 0.1% to approximately 0.3%, approximately 0.1% to approximately 0.2%, approximately 0.2% to approximately 1.0%, approximately 0.2% to approximately 0.8%, approximately 0.2% to approximately 0.6%, approximately 0.2% to approximately 0.4%, approximately 0.4% to approximately 1.0%, approximately 0.4% to approximately 0.8%, approximately 0.4% to approximately 0.6%, approximately 0.6% to approximately 1.0%, approximately 0.6% to approximately 0.8%, or approximately 0.8% to approximately 1.0%).
[0168] Furthermore, in order to improve the stability of microspheres during freeze-drying, the compositions / preparations or microspheres according to this disclosure may further contain an excipient selected from mannitol, trehalose, sucrose, and sodium carboxymethylcellulose in an amount of about 5% (W / W) to about 30% (W / W), for example, about 10% (W / W) to about 20% (W / W), based on the weight of the composition or microspheres, which includes exendin, GLP-1, or a therapeutically effective GLP-1 or exendin analog, a biodegradable polymer, and a coating material.
[0169] Furthermore, the compositions, preparations, or microspheres relating to this disclosure may further contain any additives and excipients conventionally used in pharmaceutical preparations, the types and amounts thereof which can be easily determined by those skilled in the art.
[0170] Controlled-release microspheres containing exendin, GLP-1, or a therapeutically effective GLP-1 or exendin analog used in the method relating to this disclosure may be prepared by various controlled-release microsphere preparation methods, such as suspending the microspheres in a coating material solution during or after preparation to coat the surface of the microspheres. Microsphere preparation methods may be carried out by double emulsion method (W / O / W method), single emulsion method (O / W method), phase separation method, and spray drying method.
[0171] Specifically, a method for preparing controlled-release microspheres containing exendin, GLP-1, or a therapeutically effective GLP-1 or exendin analog may include the steps of: mixing an active agent and a biodegradable polymer to prepare a W / O emulsion or homogeneous mixture; and adding this emulsion or homogeneous mixture to an aqueous solution of a coating material to emulsify and form a coating layer.
[0172] More specifically, when using the double emulsion method, this method may include the steps of: mixing an aqueous solution of the active ingredient with a biodegradable polymer dissolved in an organic solvent to emulsify and form a primary emulsion (W / O type); suspending this emulsion in an aqueous solution of the coating material to form a W / O / W type emulsion; heating the W / O / W type emulsion to remove the solvent and harden the resulting microspheres; recovering and washing the hardened microspheres; and freeze-drying the resulting microspheres. The organic solvent may be any organic solvent that can form an emulsion when mixed with the aqueous solution after dissolving the biodegradable polymer, for example, one or more selected from the group consisting of chloroform, ethyl acetate, methylene chloride, and methyl ethyl ketone (for example, methylene chloride). In this case, the coating material is contained in the second aqueous phase (the aqueous phase outside the W / O / W emulsion), and therefore, after the removal of the organic solvent, a coating layer is formed on the outside of the microspheres containing at least one active ingredient (e.g., exendin, GLP-1, or a therapeutically effective GLP-1 analog or exendin-4 analog, or a combination thereof) and a biodegradable polymer.
[0173] Alternatively, when using the single emulsion method, this method may include the steps of: dissolving the active ingredient and the biodegradable polymer in an organic solvent to form a homogeneous mixture; adding an aqueous solution containing a coating material to the obtained mixture to form an emulsion; heating the emulsion to remove the solvent and harden the obtained microspheres; recovering and washing the hardened microspheres; and freeze-drying the obtained microspheres. The organic solvent may be any organic solvent that can completely mix the active ingredient and the biodegradable polymer to form a homogeneous mixture and can mix with the aqueous solution to form an emulsion. For example, the organic solvent may be a mixed solvent obtained by mixing one or more selected from the group consisting of alcohols having 1 to 5 carbon atoms, glacial acetic acid, formic acid, dimethyl sulfoxide, and n-methylpyrrolidone with one or more selected from the group consisting of chloroform, ethyl acetate, methyl ethyl ketone, and methylene chloride, or a mixed solvent obtained by mixing methanol and methylene chloride, for example. In this case, a homogeneous mixture of the biodegradable polymer and the active ingredient is emulsified, and the coating material is added to an aqueous solution to remove the organic solvent, thereby forming a coating layer on the surface of the final microspheres.
[0174] A method for preparing controlled-release microspheres may include the steps of: mixing an active ingredient with a biodegradable polymer to form an emulsion or homogeneous mixture; solidifying the obtained emulsion or homogeneous mixture to prepare primary microspheres; and suspending the obtained primary microspheres in an aqueous solution of a coating material to form a coating layer on each microsphere.
[0175] The solidification method is not limited and may be any solidification method conventionally used in related technologies, such as a phase separation method or a spray drying method. More specifically, when a phase separation method is used in the solidification process, this method may include the steps of: mixing an aqueous solution of the active ingredient with a biodegradable polymer dissolved in an organic solvent to form an emulsion, or mixing the active ingredient and the biodegradable polymer in a mixed solvent to form a homogeneous mixture solution; adding an oil such as silicone oil to the obtained emulsion or solution to prepare primary microspheres; adding a non-solvent for the biodegradable polymer, such as a mixed solvent of an alcohol having 1 to 5 carbon atoms and an alkane having 1 to 12 carbon atoms, such as a mixed solvent of ethanol and heptane, to remove the organic solvent from the microspheres and harden the microspheres; suspending the obtained microspheres in an aqueous solution of a coating material to form a coating layer on each microsphere; and recovering, washing, and freeze-drying the microspheres on which the coating layer has been formed.
[0176] The organic solvent may be one or more selected from the group consisting of chloroform, ethyl acetate, methylene chloride, and methyl ethyl ketone (e.g., 1, 2, 3, or 4) (e.g., methylene chloride). The mixed solvent may be a mixture of one or more selected from the group consisting of at least one alcohol having 1 to 5 carbon atoms, glacial acetic acid, formic acid, dimethyl sulfoxide, and n-methylpyrrolidone (e.g., 1, 2, 3, 4, 5, or more) and one or more selected from the group consisting of chloroform, ethyl acetate, methyl ethyl ketone, and methylene chloride (e.g., 1, 2, 3, or 4) (e.g., a mixed solvent of methanol and methylene chloride).
[0177] Alternatively, when using the spray drying method, this method involves mixing an aqueous solution of the active ingredient with a biodegradable polymer dissolved in an organic solvent to form an emulsion, or mixing the active ingredient and the biodegradable polymer in a single solvent or a mixed solvent to form a homogeneous mixture solution; spray drying the resulting emulsion or solution to prepare primary microspheres; suspending the obtained primary microspheres in an aqueous solution of the coating material to form a coating layer on each microsphere; and washing and freeze-drying the microspheres with the coating layer formed thereon.
[0178] The organic solvent may be at least one (e.g., 1, 2, 3, or 4 types) (e.g., methylene chloride) selected from the group consisting of chloroform, ethyl acetate, methylene chloride, and methyl ethyl ketone. The single solvent may be at least one (e.g., 1, 2, 3, 4, or 5 types) selected from the group consisting of glacial acetic acid and formic acid, and the mixed solvent may be at least one (e.g., 1, 2, 3, 4 types, or more) selected from the group consisting of at least one alcohol having 1 to 5 carbon atoms, glacial acetic acid, formic acid, dimethyl sulfoxide, and n-methylpyrrolidone, mixed with at least one selected from the group consisting of chloroform, ethyl acetate, methyl ethyl ketone, and methylene chloride (e.g., a mixed solvent of methanol and methylene chloride).
[0179] The above method may further include a step of adding a protective colloid material by any conventional method, for example, adding a protective colloid material in the step of coating the microspheres with the coating material.
[0180] The concentration of the coating material dissolved in an aqueous phase or aqueous solution may be from about 0.01 M to about 1 M (e.g., from about 0.1 M to about 0.5 M, from about 0.01 M to about 0.8 M, from about 0.01 M to about 0.6 M, from about 0.01 M to about 0.4 M, from about 0.1 to about 1 M, from about 0.1 M to about 0.8 M, from about 0.1 M to about 0.6 M, from about 0.1 M to about 0.4 M, from about 0.2 to about 1 M, from about 0.2 M to about 0.8 M, from about 0.2 M to about 0.6 M, from about 0.2 M to about 0.4 M, from about 0.4 to about 1 M, from about 0.4 M to about 0.8 M, from about 0.4 M to about 0.6 M, from about 0.6 to about 1 M, from about 0.6 M to about 0.8 M, or from about 0.8 M to about 1 M). If the concentration of the coating material is lower than the above range, the surface of the microspheres cannot be completely coated with the coating material. If the concentration of the coating material is higher than the above range, the coating material solution will be supersaturated, and thus the effect of controlling the initial burst cannot be improved. Therefore, the concentration of the coating material may be within the above range.
[0181] Administration The controlled release composition according to the present disclosure may be administered by an oral or parenteral route (e.g., parenteral route), such as an intravenous route, subcutaneous route, intramuscular route, and intraperitoneal route. Thus, in one embodiment of the present disclosure, the controlled release composition or preparation may be administered as an injection solution in the form of a dispersion solution. The effective amount of the composition may be appropriately adjusted according to the age of the subject, the type and severity of the disease, and the condition of the subject. The amount of the active ingredient in the composition may be from about 0.01 to about 100 μg / kg / day (e.g., from about 0.1 to about 10 μg / kg / day), and this amount may be administered once or divided into multiple doses. The exact required amount may vary depending on the type of polypeptide and the individual subject, and may vary depending on the species, age, general condition of the subject, severity of the disease to be treated, specific polypeptide used, and its administration mode. Therefore, it is impossible to specify the exact "insulin secretion amount" or the amount useful for treating neurological diseases or injuries. However, an appropriate amount may be determined by those skilled in the art using only conventional experimental methods.
[0182] Those skilled in the art will understand how to monitor the effectiveness of the treatment and how to adjust it accordingly. For example, by monitoring blood glucose levels, if they are normal blood glucose, it can be assumed that the treatment is optimally effective. If blood glucose levels are higher than the preferred level, the polypeptide dose should be increased; if blood glucose levels are lower than the preferred level, the polypeptide dose should be decreased.
[0183] The compound may be administered orally, intravenously, intramuscularly, intraperitoneally, locally, percutaneously, topically, systemically, intraventrally, intracerebrally, subdurally, or subarachnoidally. Those skilled in the art will know that the mode of administration, pharmacological carrier, or other parameters can be modified to optimize the insulin secretion effect. The amount of active compound administered will, needless to say, depend on the patient, the patient's weight, the method of administration, and the judgment of the prescribing physician.
[0184] Depending on the intended mode of administration, the dosage form of the pharmaceutical composition may be solid, semi-solid, or liquid, such as tablets, suppositories, pills, capsules, powders, solutions, suspensions, lotions, creams, or gels, and may be a unit dosage form suitable for administering a precise single dose. As described above, the composition comprises a combination of an effective amount of the selected drug and a pharmaceutically acceptable carrier, and further, the composition may include other pharmacokinetics, pharmaceuticals, carriers, adjuvants, diluents, etc. See, for example, Remington's Pharmaceutical Sciences, latest edition, by EW Martin Mack Pub. Co., Easton, PA. This document discloses typical carriers and conventional methods for preparing pharmaceutical compositions that may be used in conjunction with the preparation of polypeptide preparations, and is incorporated herein by reference. With regard to solid compositions, conventional non-toxic solid carriers include, for example, pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, and magnesium carbonate. Liquid pharmaceutically administerable compositions can be prepared, for example, by dissolving, dispersing, etc., an active compound and any pharmaceutical adjuvant, as described herein, in an excipient such as water, saline aqueous dextrose, glycerin, and ethanol to obtain a solution or suspension. If it is desirable that the pharmaceutical composition to be administered further contains trace amounts of non-toxic adjuvants such as wetting agents or emulsifiers and pH buffers, such as sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, and triethanolamine oleate, these may be included. Methods for actually preparing such dosage forms will be well known or obvious to those skilled in the art. See, for example, Remington's Pharmaceutical Sciences, referenced above.
[0185] For oral administration, the fine powder or granules may contain diluents, dispersants, and / or surfactants, and the fine powder or granules may be in the form of being present in water or syrup, or dried and made into capsules or sachets, or in the form of a non-aqueous solution, or in the form of a non-aqueous suspension which may contain a suspending agent, or in the form of a tablet which may contain a binder and a lubricant, or in the form of a suspension suspended in water or syrup. Flavoring agents, protective agents, suspending agents, thickeners, or emulsifiers may be included if it is desirable or necessary to include them. In certain embodiments, the oral administration form is a tablet or granule which may be coated. When administering the parental drug, administration is generally carried out by injection.
[0186] Injectable preparations may be prepared in conventional forms, such as a solution or suspension, or as a solid form suitable for dissolution or suspension in a liquid before injection, or as an emulsion. In recent modified methods for parental administration, the dose is maintained at a constant level by using a delayed-release or sustained-release system. See, for example, U.S. Patent No. 3,710,795 (this patent is incorporated herein by reference).
[0187] For local administration, any formulation that can deliver the active compound to the skin surface may be used, such as a liquid, suspension, lotion, cream, or gel.
[0188] Examples The following examples are presented for the purpose of fully disclosing and illustrating to those ordinary skill in the art how the compounds, compositions, articles, devices, and / or methods claimed herein are formed and evaluated, and are purely intended to illustrate examples of the disclosure and not to limit the scope of the disclosure as perceived by the inventors. While every effort has been made to ensure accuracy of numerical values (e.g., quantities, temperatures, etc.), some error or deviation should be taken into consideration.
[0189] Statistics: Each value is expressed as ±SEM. The normality of the distribution was determined by the Kolmogorov-Smirnov test. Statistical analyses, as shown in the results section, were performed using Student's t-test, Mann-Whitney test, Fisher's exact test, or one-way and two-way ANOVA. Rank-based ANOVA was performed when the assumption of normality was not met. All multiple paired comparisons were performed ex post facto Newman-Kuhls test or Dunn test, and statistical significance was defined as p < 0.05.
[0190] Example 1. Pharmacokinetics and sustained plasma release of exendin-4. PT302 is a sustained-release preparation of exendin-4 containing a mixture of polymer (98%) and exendin-4 (2%). Plasma levels of exenatide were analyzed after injection of the sustained-release preparation of exendin-4 (PT302). In particular, the pharmacokinetics of a single dose of PT302 were investigated using six adult (9-week-old) male Sprague-Dawley rats. PT302 was dissolved in a fresh diluent and administered subcutaneously at a dose of 2 mg / kg. Blood samples were collected at 0, 0.5, and 1 hour after injection, and also on days 1, 3, 5, 7, 9, 11, 14, 18, 21, and 26 post-injection. Plasma levels of exendin-4 were quantified using the Peptron Exenatide EIA Kit (Peptron, Daejeon, Korea). The data are shown in Figure 1A. In the figure, Cmax is 1.85 ng / ml, Tmax is 12.5 days, and AUC is 18.55 ng * The value is d / ml (calculated from individual data from all 6 animals). As shown in Figure 1A, a single subcutaneous injection of the sustained-release preparation PT302 achieves acceptable long-term exendinine-4 plasma levels within a 1-2 week dosing regimen.
[0191] The pharmacokinetics of single-dose PT302 at various doses (2.4 mg / kg, 4.8 mg / kg, and 9.6 mg / kg) were investigated using six adult (9-week-old) male Sprague-Dawley rats for each group. PT302 was freshly dissolved in a diluent and administered subcutaneously as described above. Blood samples were collected at 0, 0.5, and 1 hour after injection, and on days 1, 3, 7, 10, 14, 17, 21, 24, 28, and 31 post-injection. Plasma levels of exendin-4 were quantified as described above. The data are shown in Figure 1B. In the figure, the Cmax for the 2.4 mg / kg dose was 2.23 ng / ml, the Tmax was 14.83 days, and the AUC was 21.13 ng. * The values were d / ml, with a Cmax of 5.21 ng / ml, Tmax of 16.17 days, and AUC of 49.46 ng at a dose of 4.8 mg / kg. * The values are d / ml, and at a dose of 9.6 mg / kg, the Cmax was 9.42 ng / ml, the Tmax was 17.17 days, and the AUC was 87.14 ng * The value is d / ml. As shown in Figure 1B, a single subcutaneous injection of the sustained-release preparation PT302 achieves long-term exenzine-4 plasma levels directly related to the dose level of PT302 administered.
[0192] PT304 is a sustained-release preparation of exendin-4, containing a mixture of polymer (96%) and exendin-4 (4%). Plasma levels of exenatide were analyzed after injection of the sustained-release preparation of exendin-4 (PT304) into six adult (9-week-old) male Sprague-Dawley rats. PT304 was dissolved in a fresh diluent and administered subcutaneously at a dose of 4 mg / kg. Blood samples were collected 1 and 3 hours after injection, and on 1, 4, 7, 11, 14, 18, 21, 25, 28, 32, 35, 39, and 42 days post-injection. Plasma levels of exendin-4 were quantified using the Peptron Exenatide EIA Kit. The data are shown in Figure 2. In the figure, Cmax was 3.82 ng / ml, Tmax was 14.17 days, and AUC was 48.34 ng. *The value is d / ml (calculated from individual data from all 6 animals). As shown in Figure 2, a single subcutaneous injection of the sustained-release preparation PT304 achieves acceptable long-term exendinine-4 plasma levels within a 2-4 week dosing regimen.
[0193] The pharmacokinetics of PT302 were investigated over 10 weeks using 10 adult (9-week-old) Sprague-Dawley rats in each group. Rats were subcutaneously injected with either PT302 at a dose of 2 mg / kg once weekly, or PT304 at a dose of 4 mg / kg every other week. PT302 and PT304 were prepared as described above, and blood samples were collected 1 and 3 hours after the first injection, and on days 1, 3, 5, 7, 10, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84, and 91 after the first injection. Serum levels of exendin-4 were quantified as described above and are shown in Figure 3. Rats injected once weekly had a Cmax of 5.27 ng / ml, a Tmax of 51.60 days, and an AUC of 236.42 ng * In rats injected every other week at a dose of d / mL, the Cmax was 5.08 ng / ml, the Tmax was 47.89 days, and the AUC was 211.51 ng. * The result was d / mL.
[0194] Example 2. In a 6-OHDA Parkinson's disease rat model, Meth-mediated circling behavior is reduced by pretreatment with PT302.
[0195] The animals were treated with a vehicle (9 rats), PT302 at a dose of 0.4 mg / kg (low dose, 9 rats), or PT302 at a dose of 2 mg / kg (high dose, 10 rats) on the days indicated in Figure 4A (i.e., 16 and 2 days before inflicting unilateral injury to the medial forebrain bundle with 6-OHDA, and 12, 26, and 40 days after injury). As shown in Figures 4A and 4B, meth-mediated circling behavior in rats was examined on 20, 30, and 45 days after injury, and the rats were euthanized on 47 days. The injury was inflicted as follows: Rats were anesthetized with chloral hydrate (400 mg / kg, intraperitoneal) and placed in a stereotactic device. Using a Hamilton microsyringe held in a stereotactic arm, 6-OHDA (2.76 μg / μl × 5 μl, containing 0.2 mg / ml ascorbic acid in 0.9% NaCl) was injected unilaterally into the medial forebrain bundle (-4.4 mm AP, 1.2 mm ML from the bregma, 8.4 mm subcranially) over 4 minutes. A micromanipulator attached to the stereotactic device was used to lower the microsyringe to position it at the desired target site in the brain. A syringe pump (Micro 4, WPI, Sarasota, FL) was used to control the injection rate (0.5 μl / min). The needle was withdrawn 5 minutes after injection. Bone wax was applied to the cranial perforation to prevent fluid leakage. The wound was sutured or clipped. Body temperature was monitored with a thermistor probe, and a heating pad was used to maintain body temperature at 37°C during anesthesia. After recovery from anesthesia, the body temperature was maintained at 37°C for an additional 3 hours using a temperature-controlled incubator.
[0196] Meth-induced ganglion behavior [Liu DM, Lin SZ, Wang SD, Wu MI, Wang Y. Xenografting human T2 sympathetic ganglion from hyperhidrotic patients partially restores catecholaminergic functions in hemi-Parkinsonian athymic rats. Cell Transplant 1999;8:563-91; and Luo Y, Hoffer BJ, Wang Y. Rotation, Drug-induced. In: Kompoliti K, Verhagen Metman L, editors. Encyclopedia of Movement Disorders. Oxford: Academic Press, 2010. p 49-51] was evaluated using an 8-channel rotometer system (RotoMax, AccuScan Instruments). As previously described [Yin LH, Shen H, Diaz-Ruiz O, Backman CM, Bae E, Yu SJ, Wang Y. Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease. BMC Neurosci 2012;13:120], animals were administered methamphetamine (2.5 mg / kg) 6 days after 6-OHDA injury. Methamphetamine is an indirect agonist that induces dopamine release in the brain. Rats injected unilaterally with 6-OHDA into the substantia nigra dopaminergic system were used as a PD model. Animals administered an indirect dopaminergic agonist (e.g., methamphetamine) exhibited ipsilateral circling behavior after administration, while animals administered a direct dopaminergic agonist (e.g., apomorphine) exhibited contralateral circling behavior after administration. This behavior is related to a unilateral alteration in the expression of dopaminergic markers in the striatum.
[0197] As shown in Figure 4B, PT302 treatment significantly reduced circling behavior in the PT302-treated group at both high and low doses, compared to vehicle levels (p=0.018, F2.87=4.309, two-directional ANOVA for the low-dose group). Post-hoc Newman-Kuhls tests showed that high doses of PT302 significantly attenuated meth-mediated circling behavior (p=0.037). Therefore, the effect of unilateral 6-OHDA injury to the medial forebrain bundle on behavior in rats (a well-characterized animal model of PD) was significantly suppressed by continuous and stable administration of exendin-4 as PT302, demonstrating neuroprotective activity.
[0198] The plasma levels of exendin-4 were quantified as described above. As shown in Figure 4C, the mean exendin-4 plasma levels were 30.845 pg / ml (n=10) in high-dose rats and 8,990 pg / ml (n=9) in low-dose rats. However, after excluding outlier rats and measurements (rats 1, 10, and 12), the mean exendin-4 plasma levels were 5,596 pg / ml (n=8) in high-dose rats and 574 pg / ml (n=8) in low-dose rats.
[0199] Example 3. In 6-OHDA-injured rats, meth-induced circling behavior was reduced by post-treatment with PT302. The unilateral medial forebrain fascicle injury of the PD rodent model with 6-OHDA, as described in Example 2, and post-treatment with a high-potency drug can be combined as shown in the scheme in Figure 5A. In this case, the rodents are given a unilateral injury with 6-OHDA (day 0), and treatment is started 6 days later. This PD rodent model is more difficult to treat because dopaminergic cell death has already begun and is progressing before treatment. Nineteen rats were injured as described above. As described above, meth-induced circling behavior was investigated, and animals with more than 300 circlings per hour were divided into two groups so that the number of circling behaviors in the vehicle group and the PT302 group before treatment was the same. As outlined in Figure 5A, meth-induced circling behavior was investigated 6, 20, 30, and 45 days after injury. Animals (adult male Sprague-Dawley rats, 2 months old at acquisition) were treated with vehicle (subcutaneously, n=11) or PT302 (100 mg / kg, containing 2.0 mg / kg of exenzine-4, subcutaneously, n=8) on 6, 20, and 34 days after 6-OHDA injury. PT302 was prepared as described above. On 47 days post-injury, the animals were euthanized. Blood and brain samples were collected, and plasma was separated and stored (-80°C). Exenzine-4 in the collected plasma was measured.
[0200] As shown in Figure 5B, meth-induced circling behavior in unilateral 6-OHDA injured rats was significantly reduced by PT302 compared to vehicle controls (p=0.032, bidirectional ANOVA).
[0201] TH was examined by immunohistochemical analysis. Specifically, serial cryostat sections with a thickness of 25 μm were cut from the whole brain. One out of every six sections was stained for TH examination. For the purpose of controlling staining variability, specimens from all experimental groups were included in each batch and reacted together under the same conditions in one multiwell tray. The sections were rinsed in 0.1 M phosphate buffer (PB), and blocked with a 0.1 M PB solution containing 4% bovine serum albumin (BSA) and 0.3% Triton x-100. Subsequently, the sections were incubated in the primary antibody (mouse anti-TH monoclonal antibody, diluted in a 0.1 M PB solution containing 4% BSA and 0.3% Triton x-100, concentration 1:100; Chemicon, Temecula, CA) at 4°C for 17 - 19 hours. Then, the sections were rinsed in 0.1 M PB, incubated in the secondary antibody for 1 hour, and subsequently incubated with an avidin-biotin-peroxidase complex for 1 hour. The sections were placed on glass slides and covered with coverslips.Control sections were incubated without primary antibody.
[0202] TH immunoreactivity in the striatum was measured by ImageJ, and three brain sections where the anterior commissure was visible were selected and their average value was determined. TH immunoreactivity in the substantia nigra was measured every 360 μm across the entire midbrain (from -4.2 mm to -6.0 mm from bregma). Five brain sections per animal were used. The volume of the substantia nigra was analyzed by the Cavalieri’s method.
[0203] 6-OHDA-mediated dopaminergic neurodegeneration in the striatum was reduced by PT302. Representative striatal TH immunostaining results and plasma exendin-4 levels for three vehicle-administered rats (#866, 883, 886) and three PT302-administered rats (#881, 875, 882) are shown in Figure 5C (quantified plasma exendin-4 concentrations from the same animals are also shown in Figure 5C). As shown in Figure 5D, striatal TH immunoreactivity in vehicle-administered animals was significantly reduced by 6-OHDA injection, while TH immunoreactivity in injured striatum was significantly increased by PT302. * p<0.001, bidirectional ANOVA). L = injured side, non-L = uninjured side, veh = vehicle-administered animal, PT = PT302.
[0204] TH immunoreactivity in the substantia nigra was measured by ImageJ, and the mean values were calculated for three brain sections showing the anterior commissure. Representative TH immunostaining results for vehicle-administered animals (rats #866, #883, #886) or PT302-administered animals (rats #881, #875, #882) are shown in Figure 5E (plasma levels of exendin-4 from the same animals are also indicated). Quantitative TH immunoreactivity in the substantia nigra at 360 μm intervals from -4.2 mm to -6 mm from the bregma is shown in Figure 5F. TH immunoreactivity in the substantia nigra was significantly reduced by 6-OHDA injection in vehicle-administered animals, while the loss of TH immunoreactivity in injured substantia nigra was significantly suppressed by PT302. * p<0.001, bidirectional ANOVA). L = injured side, non-L = uninjured side, veh = vehicle-administered animal, PT = PT302 Post-treatment with PT302 protects TH+ neurons in the injured substantia nigra. Brain sections were prepared and immunohistochemical examination was performed as described above. TH+ neurons were observed on the uninjured side of the brain (Figures 5G and 5H). Few TH+ neurons or fibers were observed in the substantia nigra on the injured side of the brain (rat #886, Figure 5I). Some TH+ neurons were protected by PT302 treatment (Figures 5J, 5K, and 5L).
[0205] Exendin-4-mediated protection in TH neurons is associated with plasma exendin-4 levels. Figure 5M shows a significant correlation observed between standardized striatal TH (i.e., injured / uninjured) immunoreactivity and plasma exendin-4 levels in the same animals (p=0.002, R=0.663). Figure 5L shows a significant correlation observed between plasma exendin-4 levels and TH immunoreactivity in the substantia nigra on the injured side (p<0.001, R=0.842).
[0206] Example 4. Meth-mediated circling behavior in a 6-OHDA PD rat model is reduced by pretreatment with PT302. As shown in Figure 6A, as described above, animals were subcutaneously treated with Ex-4 (5 μg / kg, BID) or PT302 (0.4 mg / kg) 7 days before and 7 days after 6-OHDA injury. The exenzine-4 dose of 5 μg / kg BID used in this experiment is higher than the dose available for use in humans (see Table 1 below), while a lower dose of approximately 1 μg / kg BID is equivalent to both the human dose and the PT302 dose used in this experiment. Both Ex-4 (5 μg / kg, BID) treatment and PT302 (0.4 mg / kg) treatment significantly reduced circling behavior in 6-OHDA injured rats (p=0.005 for the Ex-4 group, p=0.002 for the PT302 group) (Figure 6B).
[0207] Pretreatment with either Exendin-4 or PT302 provided protection against 6-OHDA-mediated dopaminergic neurodegeneration in the substantia nigra. Representative TH immunoreactivity results for sham animals and 6-OHDA-injured animals administered with vehicle, Ex-4 (5 μg / kg, BID), or PT302 (0.4 mg / kg) are shown in Figure 6C. TH immunoreactivity on the injured side was significantly reduced by 6-OHDA injection (indicated as ipsi in Figure 6C). Representative TH immunoreactivity in the substantia nigra is quantified in Figure 6D. Loss of TH immunoreactivity on the 6-OHDA-injured side was significantly reduced by treatment with PT302 and Ex-4 (evaluation was performed by expressing TH immunoreactivity as the percentage ratio of immunoreactivity of the injured side (ipsi) of the same animal to immunoreactivity of the control (non-injured side)).
[0208] Example 5. Meth-mediated circling behavior in a 6-OHDA Parkinson's disease rat model is reduced by post-treatment with PT302. As described above, after 6-OHDA injury, animals were treated with Ex-4 (1 μg / kg, BID from day 2) or PT302 (0.4 mg / kg, once on day 2), and meth-mediated circling behavior was examined on day 9 post-injury (Figure 7A). As shown in Figure 7B, circling behavior in unilateral 6-OHDA injured rats was significantly reduced by PT302 (p=0.0075). In contrast, exendin-4 did not reduce circling behavior in unilateral 6-OHDA injured rats. Therefore, in the 6-OHDA rat PD model, using exenzine-4 at a dose equivalent to that used in humans (1 μg / kg, BID for rats) did not suppress meth-induced circling behavior, but it was demonstrated that using PT302 at a dose equivalent to that used in humans was effective. When the dose of exenzine-4 was increased to a dose higher than that usable in humans (5 μg / kg, BID, shown in Example 4), exenzine-4 was also able to suppress 6-OHDA-induced abnormalities. In contrast, a dose of PT302 equivalent to the clinical dose showed a favorable effect in both Examples 4 and 5.
[0209] Example 6. Toxin-induced behavioral defects in an MPTP PD mouse model were improved by post-treatment with PT302. As described above, after induction of Parkinson's syndrome with MPTP, animals were treated with Ex-4 (16.7 ug / kg, BID from day 6) or PT302 (0.6 mg / kg; days 6, 20, and 34) (Figure 8A). Specifically, Parkinson's syndrome was induced by systemic administration of MPTP at 30 mg / kg once daily for 5 days. See, for example, Filichia E, Hoffer B, Qi X, Luo Y. Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson's disease model induced by MPTP. Sci Rep. 2016;6:32656. Treatment with either Ex-4 or PT302 was initiated one day after the first MPTP administration and continued for 18 days. The selected doses, Ex-4 (16.7 ug / kg, BID, subcutaneous) and PT302 (0.4 mg / kg, single subcutaneous dose), were equivalent in that the amount of Ex-4 delivered and provided over 18 days of treatment was 601.2 ug / kg and less than 600 ug / kg, respectively. On day 18, motor coordination was assessed in all groups of animals by the wire grip test. The wire grip test (also known as the paw grip endurance (PaGE) method and grip force-recording test) is often used as an indicator of motor ability. PaGE was designed to assess grip strength in mice, and grip strength can indicate a decrease in motor ability.In this specification, PaGE was performed according to the description by Jessica AL et al. (Jessica AL Hutter-Saunders, Howard E. Gendelman, R. Lee Mosley. Murine Motor and Behavior Functional Evaluations for Acute 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Intoxication. J Neuroimmune Pharmacol. 2012;7(1):279-288). Briefly, each mouse was removed from a conventional rodent cage, placed on a wire lid, and the lid was gently shaken to allow the mouse to grasp it, then the lid was turned upside down (180 degrees). The waiting time until both hind limbs of the mouse detached was measured in seconds. Each mouse was subjected to the test three times, with a maximum duration of 240 seconds at random, and the longest waiting time until it fell or its hind limbs separated was recorded (Jessica, et al. 2012).
[0210] As shown in Figure 8B, administration of the dopaminergic cytotoxin MPTP significantly reduced the waiting time in the grip test (94.5 seconds for MPTP compared to 148.3 seconds for the control group without MPTP, p=0.02). The time it took for MPTP-treated mice to fall from the wire was significantly longer with PT302 (118.3 seconds, no statistical difference from the aggregate value of the control group), but exendin-4 (administered twice daily, using a method similar to human administration of Byetta (i.e., immediate-release Ex-4)) did not suppress the toxin-induced behavioral defect in MPTP-treated mice (72.9 seconds, p+0.01 compared to the aggregate value of the control group) (Figure 8B: 7-10 mice per group).
[0211] Example 7. Delivery of Ex-4 to the central nervous system using sustained-release exendin-4 is effective in achieving a therapeutically effective dose of exendin-4 in the cerebrospinal fluid. Exendin-4 (injection and minipump) and the sustained-release preparation of exendin-4 (PT302) were administered to adult male Sprague-Dawley rats (9 weeks old) used in this experiment as shown in Table 1. Fourteen days after the first injection of exendin-4, blood and cerebrospinal fluid (CSF) were collected to measure exendin-4 levels. The plasma and CSF levels of exendin-4 were quantified as described above. As shown in Table 2, exendin-4 was detected in plasma and CSF in the sustained-release preparation group and the minipump-administered exendin-4 group, but in the group receiving exendin-4 twice daily (BID, immediate-release), the level of exendin-4 in CSF was below the detection limit. In contrast to these results, high levels of exendin-4 were detected in the plasma of the same exendin-4 group. In the pump-administered exendin-4 group at doses of 3.5–15 pM / kg / min, the CSF level / plasma level ratio was observed to be 0.0081 (or 0.81%) to approximately 0.0412 (or 4.12%), with a mean of 0.018 (or 1.8%). Similarly, in animals administered PT302 at 0.46–2.0 mg / kg / 14 days, the CSF / plasma level ratio was 0.0117 (or 1.17%) to approximately 0.016 (or 1.6%). These data suggest that sustained release of exendin-4 provides even higher levels of exendin-4 into the CNS.
[0212] [Table 1]
[0213] [Table 2]
[0214] Example 8. Novel object recognition is improved in mice with mild traumatic brain injury (mTBI) by treatment with sustained-release exenatide. As previously described (Tweedie et al. 2007), a drop weight impact device was used to inflict injury to the head. The device consisted of a metal tube (90 cm long, 1.3 cm inner diameter) and a sponge placed beneath the tube to support the mouse's head. The mouse was lightly anesthetized by isoflurane inhalation and placed beneath the device. A metal weight (30 grams) was dropped from the top of the tube, striking the mouse's head on the temporal side, between the edge of the eye and the ear. Immediately after the injury, the mouse was returned to its original cage for recovery. Mice were able to tolerate this head injury treatment well, and the treatment resulted in widespread neuronal reduction in the hippocampus and cerebral cortex on the injured side, leading to cognitive impairment in visual and spatial memory tests (Deselms H, Maggio N, Rubovitch V, Chapman J, Schreiber S, Tweedie D, Kim DS, Greig NH, Pick CG. Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development. J Neurosci Methods. 2016;272:69-76).
[0215] One hour after head injury, sustained-release PT302 was administered (0.6 mg / kg, subcutaneously) as described above (Figure 9A). Seven days after injury, the mice were subjected to a novel object recognition paradigm test. This test is conventionally used to evaluate recognition memory in rodents. Uninjured rodents innately tend to explore novel objects if they are nearby. Because mice possess this behavioral characteristic, it is possible to evaluate their visual recognition memory function. Perhaps more importantly, because they possess this behavioral characteristic, it is possible to evaluate the effects of various stimuli on this innate behavior. Two experiments are conducted in this test. In the first experiment, the animals are asked to examine two objects for a set amount of time (5 minutes). In the second experiment, conducted 24 hours after the first experiment, the animals are given two objects: the same object given in the first experiment and a new object. In the second experiment, mice were instructed to search for these two objects for 5 minutes. A discrimination preference index was calculated and used to evaluate the animals' recognition memory. The index was calculated as follows: the time the animal spent near the known object was subtracted from the time the animal spent near the new object, and this result was divided by the sum of the time the animal spent near the new object and the time the animal spent near the known object (Dix SL, Aggleton JP. Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition. Behav. Brain Res. 1999;99:191-200). As shown in Figure 9B, exenatide administration significantly increased novel object recognition in mTBI mice (n=5) compared to untreated mTBI mice (n=7), indicating that mTBI-induced visual recognition abnormalities were suppressed in PT302-treated mice.
[0216] Example 9. Examination of plasma exendin-4 levels in normal ICR mice. Plasma exendin-4 concentrations were measured 7 days after subcutaneous administration of PT302 (0.1, 0.3, 0.6, 1.0, and 2.0 mg / kg) in normal ICR mice. Plasma levels of exendin-4 were quantified as described above. Plasma exendin-4 levels persisted up to 7 days after injection, accumulating in a dose-dependent manner to approximately 4000 pg / ml (Figure 10A).
[0217] Example 10. Examination of plasma exendin-4 levels in normal mice and traumatic brain injury mice. Exendin-4 plasma levels were measured 7 days after subcutaneous administration of PT302 (0.6 mg / kg) in normal mice and TBI model mice. Plasma levels of exendin-4 were quantified as described above. No difference in exendin-4 plasma levels was observed between normal mice and TBI-induced mice (Figure 10B).
[0218] Example 11. Sustained-release exenatide maintains exendin-4 plasma levels for an extended period. Normal ICR mice were administered a single subcutaneous injection of PT302 at three different doses (0.024 mg / kg, 0.12 mg / kg, and 0.6 mg / kg). Blood samples for plasma measurement were collected at 0, 0.5, and 1 hour after the first injection, and on days 1, 3, 7, 14, and 21. Plasma concentrations of exendin-4 were quantified as described above. As shown in Figure 10C, a single administration of PT302 maintained exendin-4 plasma levels for more than 20 days.
[0219] Example 12. Recognition of novel objects and new arms in a maze is significantly increased by sustained-release exenatide 7 days after traumatic brain injury. Mice were injured in the head as described above and promptly returned to their original cages for recovery. One hour after TBI induction, PT302 (0.024 mg / kg, 0.12 mg / kg, and 0.6 mg / kg) was administered subcutaneously by a single injection. Behavior was evaluated 7 days after mTBI (novel object recognition and Y-maze test). The Y-maze paradigm is commonly used to evaluate spontaneous exploration and response to a novel environment and spatial working memory function (Deselms, et al., 2016). The test apparatus consisted of multiple identical black plexiglass arms (8 × 30 × 15 cm), which extended from the center point at a 120-degree angle from the center. To provide mice with visual memory anchors, each arm of the maze is equipped with a different spatial cue. Typically, two experiments are conducted with a 2-3 minute interval, but here, these experiments were conducted with a 5 minute interval. In the first experiment, the starting arm is randomly selected each time. One animal is placed at the center of the Y-maze environment, and during the 5 minutes of the first experiment, one of the remaining two arms is randomly closed, and during the 2 minutes of the second experiment, all three arms are opened for exploration. The total time the mouse spends exploring each arm during the second experiment is recorded. The T-maze is carefully cleaned between experiments to avoid confusion. We evaluate whether there are differences in behavior between animal treatment groups by using the time spent in a new, unexplored arm compared to the time spent in a previously explored, known arm, i.e., ((time spent in the new arm) - (time spent in the known arm)) / ((time spent in the new arm) + (time spent in the known arm)).
[0220] Vehicle-treated mTBI mice exhibited visual memory deficits and spent less time near novel objects compared to control mice (p<0.001) (Figure 11A). Mice treated with a single subcutaneous injection of PT302 at doses of 0.12 mg / kg (p<0.05) and 0.6 mg / kg (p<0.01) one hour after mTBI induction showed a higher preference for novel objects compared to untreated mTBI mice (Figure 11A).
[0221] Mice treated with mTBI exhibited significant spatial memory abnormalities and spent less time in the new arm of the Y-maze compared to sham (control) animals (p<0.001) (Figure 11B). One hour after mTBI induction, a single subcutaneous injection of PT302 at doses of 0.12 mg / kg and 0.6 mg / kg resulted in remission of mTBI spatial memory deficits compared to untreated mTBI mice (p<0.01) (Figure 11B). [F(4,50)=4.83, p=0.002, Fisher's minimum significance method, retrospective].
[0222] For all groups, the time spent inside the open arm of the elevated cross maze was approximately equal, and it was impossible to distinguish the groups in terms of anxiety-like behavior (Figure 11C). Importantly, this showed that anxiety-like behavior was not a confounding factor in the novel object recognition and Y-maze paradigms previously tested (p>0.05) [F(4,36)=0.28, p=0.89].
[0223] Example 13. Recognition of novel objects and new arms in a maze was significantly increased by sustained-release exenatide 30 days after traumatic brain injury. Mice were injured in the head as described above and promptly returned to their original cages for recovery. One hour after TBI induction, PT302 (0.6 mg / kg) was administered subcutaneously by a single injection. Behavior was evaluated 30 days after mTBI (novel object recognition and Y-maze test).
[0224] Vehicle-treated mTBI mice exhibited visual memory deficits and spent less time near novel objects compared to control mice (p<0.001, Figure 12A). Mice treated with a single subcutaneous injection of PT302 at doses of 0.12 mg / kg or 0.6 mg / kg one hour after mTBI induction showed a higher preference for novel objects compared to mTBI mice (p<0.01 and p<0.001, respectively, Figure 12A).
[0225] Mice treated with mTBI exhibited significant spatial memory abnormalities and spent less time in the new arm of the maze compared to sham / control animals (p<0.001, Figure 12B). A single subcutaneous injection of PT302 at a dose of 0.6 mg / kg one hour after mTBI induction resulted in remission of mTBI spatial memory deficits compared to mTBI alone (p<0.01, Figure 12B).
[0226] For all groups, the time spent inside the open arm of the maze was approximately equal, and it was impossible to distinguish between the groups in terms of anxiety-like behavior (Figure 12C). This indicates that anxiety-like behavior was not a factor in the novel object recognition and Y-maze paradigms we previously investigated (p>0.05).
[0227] Example 14. The decrease in NeuN immunoreactivity following traumatic brain injury in the temporal cortex and hippocampal regions of mice was prevented by administration of PT302. NeuN is a mature neuron marker and can be used to investigate neuronal reduction resulting from traumatic brain injury. To evaluate NeuN cells in a defined brain region, mice were anesthetized with an overdose of ketamine + xylazine and rapidly perfused transcardiacally with physiologically buffered saline followed by 4% paraformaldehyde (PFA, in 0.1M phosphate buffer, pH 7.4). The brains were removed and fixed overnight (4% PFA in 0.1M phosphate buffer, pH 7.4), then placed in 30% sucrose for 48 hours. Coronal sections (30 μm) were prepared by cryostat and stored in cryoprotective material at -20°C until use. Subsequently, five cortical sections and five hippocampal sections were blocked by incubation at 25°C for 1 hour with 0.1% Triton X-100 and 10% normal horse serum in phosphate-buffered saline (PBST). Next, the primary antibody, mouse anti-neuronal nucleus antibody (NeuN; 1:50, Millipore, Danvers, MA, USA, Cat#MAB3377), was dissolved in PBST and 2% normal horse serum and incubated with the sections at 4°C for 48 hours. After rinsing in PBST, the sections were incubated with DyLight® 594-labeled AffinityPure donkey anti-rabbit IgG antibody and DyLight® 488-labeled AffinityPure donkey anti-mouse IgG antibody (1:300; Jackson Laboratories, Bar Harbor, ME, USA) at 25°C for 1 hour. After rinsing in PBST, sections were placed on dry gelatin-coated glass slides and fluorescence was evaluated using a Zeiss LSM 510 confocal microscope (Carl Zeiss, Jena, Germany) equipped with ×20 and ×63 lenses. Three to five sections were used per brain, and fluorescence was evaluated in the hippocampus and temporal cortex within a defined field of view of 140. 2 or 440 2The average cell number at μM was calculated. Immunofluorescence on immunohistochemistry slides was evaluated using a blinding method, and the primary antibody was conventionally removed when preparing negative control sections. Color quantification analysis was performed using the Imaris program (Bitplane AG, Zurich, Switzerland).
[0228] Figure 13A shows representative images of NeuN (red, at the time of color evaluation)-positive neurons in the cortex, CA3, and dentate gyrus of control mice, untreated mTBI mice, and PT302-treated mTBI mice (0.6 mg / kg 1 hour after mTBI) 30 days after mTBI. The bar graphs in Figures 13B, 13C, and 13D show the quantification of viable neurons in the cortex, CA3, and dentate gyrus, respectively. Quantification was performed using the number of neurons stained positively against NeuN in the sham control group, mTBI group, and mTBI + PT302 0.6 mg / kg group. ** p<0.01, *** (p<0.001). Values are mean ± SEM. Administration of exendin-4 as PT302 via sustained release prevented the neuronal reduction observed due to traumatic brain injury.
[0229] Example 15. The number of degenerated neurons in mTBI mice decreased with PT302 administration. Fluoro-Jade® C is a fluorescent stain that labels damaged degenerated brain neurons and can be used to investigate neuronal reduction due to traumatic brain injury. Ionized calcium-binding adapter molecule 1 (IBA1) is specifically expressed in microglia and upregulated in activated microglia. This can be used as a marker of neuroinflammation. Mice were euthanized, and their brains were prepared for immunohistochemical analysis as described above. Coronal sections (40 μm) of the hippocampus and parietal cortex were prepared using a cryostat and collected in a cryoprotective solution. In addition to the parietal cortex, CA1, CA3, and dentate gyrus from the hippocampus were also analyzed.
[0230] To perform FluoroJade C staining, brain sections were first immersed in an 80% ethanol solution containing 1% NaOH for 5 minutes. After rinsing in 70% ethanol for 2 minutes, they were washed in distilled water and then incubated in a 0.06% potassium permanganate solution for 10 minutes. After washing with water, the slides were incubated in FJC staining solution (obtained by adding 4 ml of 0.01% FJC preservative solution in distilled water to 96 ml of 0.1% acetic acid) and stained for 10 minutes. After washing three times with distilled water, the slides were thoroughly air-dried in a slide warmer, cleared in xylene, and covered with a coverslip using DPX. Fluorojade C-positive cells were counted in each region of both hemispheres using an FV 1000MPE Olympus confocal microscope.
[0231] To perform IBA1 / TNF-α dual labeling, sections were incubated for 48 hours with IBA1 antibody (goat anti-IBA1 polyclonal antibody 1:200, Abcam, USA) and TNF-α antibody (TNF-α rabbit anti-TNF-α polyclonal antibody 1:800, Abbiotec, USA). After PBS washing, sections were incubated with a secondary IBA1 antibody, and a three-step detection test was performed using biotin-labeled IgG (IgG(H+L) biotin-goat anti-rabbit 1:500, Invitrogen, USA) and streptavidin-fluorescein (1:200, Vector, UK) to enhance the TNF-α signal.
[0232] Qualitative and quantitative analyses of IBA1 and TNFα were performed using an Olympus confocal laser scanning microscope FV 1000MPE. Z-sequence images were processed with ImageJ 1.47v, and the volume of colocalization factors was measured using Imaris 7.4.2 as follows. For each dataset, a colocalization channel was automatically constructed using software. In the final layer, target regions were selected for each brain region (CA1, CA3, DG, and cortex) in each hemisphere of each animal, the volume of the target elements was calculated and summed, and expressed as volume / μm3.
[0233] As shown in Figure 14A, after mTBI injury, a significant increase in the number of Fluoro-Jade-positive neurons was observed in all investigated regions (CA1, CA3, DG, and lateral cortex of the hippocampus) compared to the control (p<0.05 for CA1; p<0.001 for CA3, DG, and CTX; Figures 14A, 14B, 14C, 14D, and 14E, respectively). Treatment with PT302 at a dose of 0.6 mg / kg counteracted the effects of mTBI-induced neurodegeneration in all investigated regions (p<0.01 for CA3 and DG, Figures 14C and 14D; p<0.05 for CTX and CA1, Figures 14E and 14B), and a dose of PT302 at 0.12 mg / kg showed a significant effect in the CA3 region (p<0.05).
[0234] As shown in Figure 15A, after mTBI injury, IBA1 immunoreactivity was increased in all analyte regions compared to the vehicle control (p<0.05 for CA1; p<0.001 for CA3, DG, and CTX). In the control group, microglial cells exhibited a resting morphology with smaller cell bodies and longer, thinner processes (Figure 15A). After mTBI injury, microglia exhibited an activated morphology characterized by larger cell bodies and shorter, thicker processes (Figure 15A). Microglial activation was inhibited by PT302 at all doses, and PT302 0.6 mg / kg was effective in all brain regions (p<0.001 for CTX, p<0.001 for CA1 and CA3, and p<0.05 for DG).
[0235] Immunoreactivity to the pro-inflammatory cytokine TNF-α was increased in all analyte regions of IBA1+ cells in the mTBI injury group (p<0.05 for DG; p<0.01 for CA1; p<0.001 for CA3 and cortex; Figures 15D, 15B, 15C, and 15E, respectively). Administration of PT302 at doses of 0.6 and 0.12 mg / kg reduced the level of IBA1 / TNF-α IR colocalization volume in both the hippocampus and cortex.
[0236] Specific Embodiments One aspect of the present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of a subject. The method comprises administering a therapeutically effective amount of a neuroprotective polypeptide into the systemic circulation of a subject using a controlled-release preparation or device that provides sustained release or sustained delivery of the neuroprotective polypeptide, wherein the neuroprotective polypeptide comprises at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation or sustained release of the neuroprotective polypeptide increases the delivery and / or uptake of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of the subject by crossing the blood-brain barrier (BBB) compared to an immediate-release preparation of the neuroprotective peptide.
[0237] Another aspect of the present disclosure provides a method for treating subjects with central nervous system (CNS) related disorders or for reducing symptoms in subjects requiring reduction of at least one symptom of a CNS related disorder. The method comprises administering a therapeutically effective amount of a neuroprotective polypeptide into the systemic circulation of a subject using a controlled-release preparation or device that provides sustained release or sustained delivery of the neuroprotective polypeptide, wherein the neuroprotective polypeptide comprises at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation or device increases the delivery of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) by crossing the blood-brain barrier (BBB) of the subject compared to a fast-release preparation of the neuroprotective polypeptide.
[0238] One aspect of the present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of a subject. The method comprises administering a controlled-release preparation containing at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog, into the systemic circulation of the subject, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery and / or uptake of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) by crossing the blood-brain barrier (BBB) of the subject compared to a fast-release preparation of the neuroprotective polypeptide.
[0239] In any aspect or embodiment described herein, the controlled-release preparation is a sustained-release preparation of a neuroprotective polypeptide.
[0240] In any embodiment or aspect described herein, a controlled-release preparation further comprises a biodegradable polymer having a specific viscosity and a coating material to achieve bioavailability and sustained release of an effective amount of neuroprotective polypeptide over a sufficient period of time (e.g., without causing an initial burst, such as a harmful initial burst of the active ingredient).
[0241] In any embodiment or aspect described herein, the controlled-release neuroprotective preparation comprises a core containing a neuroprotective polypeptide, controlled-release microspheres containing a biodegradable polymer, and a coating layer covering the core.
[0242] In any embodiment or configuration described herein, the sustained-release preparation includes a depot preparation for sustained release of a neuroprotective polypeptide.
[0243] In any embodiment or configuration described herein, the sustained-release preparation comprises a composition for the sustained release of a neuroprotective polypeptide.
[0244] In any embodiment or aspect described herein, administration of a controlled-release neuroprotective preparation alleviates at least one symptom of at least one CNS-related condition in the subject.
[0245] In any aspect or embodiment described herein, the CNS-related condition is selected from the group consisting of Parkinson's disease (PD), traumatic brain injury (TBI), multiple sclerosis, drug addiction, alcohol addiction, neurodegenerative conditions, cerebral inflammation, Alzheimer's disease (AD), multiple system atrophy, Huntington's disease, chronic traumatic encephalopathy, motor neuron diseases (e.g., amyotrophic lateral sclerosis, spinal cord injury, spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)), vascular dementia, Lewy body dementia (DLB), mixed dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, or a combination thereof.
[0246] In any aspect or embodiment described herein, administration of a controlled-release neuroprotective preparation includes injection of the controlled-release neuroprotective preparation.
[0247] In any aspect or embodiment described herein, the injection of the controlled-release neuroprotective preparation is by subcutaneous injection.
[0248] In any embodiment or configuration described herein, administration of a controlled-release neuroprotective preparation stabilizes the concentration of neuroprotective polypeptides in plasma within a range of approximately 50 to approximately 4500 pg / mL.
[0249] In any embodiment or configuration described herein, administration of a controlled-release neuroprotective preparation cumulatively increases the concentration of neuroprotective polypeptides in the cerebrospinal fluid (CSF), brain, or combination thereof of the subject.
[0250] In any embodiment or aspect described herein, the concentration of the neuroprotective polypeptide in the CSF is in the range of about 5 to about 400 pg / mL.
[0251] A further aspect of the present disclosure provides a method for treating subjects with central nervous system (CNS)-related disorders or for reducing symptoms in subjects requiring reduction of at least one symptom of a CNS-related disorder. The method comprises administering a therapeutically effective amount of a controlled-release neuroprotective preparation containing at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog, into the systemic circulation of the subject, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) by crossing the blood-brain barrier (BBB) of the subject compared to a fast-release preparation of the neuroprotective polypeptide.
[0252] In any aspect or embodiment described herein, the controlled-release preparation is a sustained-release preparation of a neuroprotective polypeptide.
[0253] In any aspect or embodiment described herein, a controlled-release preparation further comprises a biodegradable polymer having a specific viscosity and a coating material, wherein the bioavailability and sustained release of a neuroprotective polypeptide at an effective concentration continues over a period of time (e.g., without an initial burst, such as a harmful initial burst of the active ingredient).
[0254] In any embodiment or aspect described herein, the controlled-release neuroprotective preparation comprises a core containing a neuroprotective polypeptide, controlled-release microspheres containing a biodegradable polymer, and a coating layer covering the core.
[0255] In any embodiment or configuration described herein, the sustained-release preparation includes a depot preparation for sustained release of a neuroprotective polypeptide.
[0256] In any embodiment or configuration described herein, the sustained-release preparation comprises a composition for the sustained release of a neuroprotective polypeptide.
[0257] In any embodiment or aspect described herein, administration of a controlled-release neuroprotective preparation alleviates at least one symptom of at least one CNS-related condition in the subject.
[0258] In any aspect or embodiment described herein, the CNS-related condition is selected from the group consisting of Parkinson's disease (PD), traumatic brain injury (TBI), multiple sclerosis, drug addiction, alcohol addiction, neurodegenerative conditions, cerebral inflammation, Alzheimer's disease (AD), multiple system atrophy, Huntington's disease, chronic traumatic encephalopathy, motor neuron diseases (e.g., amyotrophic lateral sclerosis, spinal cord injury, spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)), vascular dementia, Lewy body dementia (DLB), mixed dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, or a combination thereof.
[0259] In any aspect or embodiment described herein, administration of a controlled-release neuroprotective preparation includes injection of the controlled-release neuroprotective preparation into a subject.
[0260] In any aspect or embodiment described herein, the injection of the control-release neuroprotective preparation into the subject is by subcutaneous injection.
[0261] In any embodiment or configuration described herein, administration of a controlled-release preparation stabilizes the concentration of neuroprotective polypeptides in plasma within a range of approximately 50 to approximately 4500 pg / mL.
[0262] In any embodiment or configuration described herein, administration of a controlled-release preparation cumulatively increases the concentration of neuroprotective polypeptides in at least one of cerebrospinal fluid (CSF), the brain, or a combination thereof.
[0263] In any embodiment or configuration described herein, the preparation is administered once every 7 to 21 days (for example, once every 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days).
[0264] In any embodiment or configuration described herein, the second administration of the preparation is performed approximately 7 to 21 days after the administration of the preceding administration (for example, once every 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days).
[0265] In any aspect or embodiment described herein, if the preparation is re-administered within approximately 28 days (e.g., within approximately 21 or 14 days) of a prior administration of the preparation, the percentage change in the concentration of the neuroprotective polypeptide in plasma is approximately 30% or less.
[0266] An additional aspect of the present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of a subject. The method comprises providing sustained delivery of at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog to the systemic circulating blood flow of the subject, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery and / or uptake of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) of the subject by crossing the blood-brain barrier (BBB) compared to a rapid-release preparation of the neuroprotective peptide.
[0267] A further aspect of the present disclosure provides a method for treating subjects with central nervous system (CNS) related disorders or for reducing symptoms in subjects requiring reduction of at least one symptom of a CNS related disorder. The method comprises providing sustained delivery of at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog to the systemic circulation of the subject, wherein the neuroprotective polypeptide binds to and activates a receptor that binds to at least one of GLP-1, exendin-4, or a combination thereof, and the controlled-release neuroprotective preparation increases the delivery of the neuroprotective polypeptide to at least a portion of the central nervous system (CNS) by crossing the blood-brain barrier (BBB) of the subject compared to a fast-release preparation of the neuroprotective polypeptide.
[0268] In any aspect or embodiment described herein, providing sustained release of (one or more) neuroprotective polypeptides includes administration of (one or more) neuroprotective polypeptides by a device (e.g., a pump, minipump, osmotic pump, osmotic delivery device, infusion pump, intravenous administration device, peristaltic pump, or miniature infusion pump).
[0269] In any embodiment or configuration described herein, when the preparation is administered (for example, once every 7 to 28 days, or once every 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days), the percentage change in the concentration of neuroprotective polypeptides in plasma at a stable state after reaching a stable state is about 80% or less (for example, about 50% or less or about 40% or less).
[0270] In any aspect or embodiment described herein, one or more neuroprotective polypeptides are administered by a device (e.g., a pump, minipump, osmotic pump, osmotic delivery device, infusion pump, intravenous administration device, peristaltic pump, or small infusion pump).
[0271] In any embodiment or configuration described herein, one or more neuroprotective polypeptides are administered at a rate of approximately 1 pM / kg / min to approximately 30 pM / kg / min (for example, approximately 3 pM / kg / min to approximately 17.5 pM / kg / min).
[0272] In any aspect or embodiment described herein, administration of a controlled-release neuroprotective preparation or provision of sustained delivery of a neuroprotective polypeptide alleviates at least one symptom of at least one CNS-related condition in a subject.
[0273] In any embodiment or configuration described herein, administration of a controlled-release preparation or provision of sustained release of a neuroprotective polypeptide stabilizes the concentration of the neuroprotective polypeptide in plasma within a range of approximately 50 to approximately 4500 pg / mL.
[0274] In any embodiment or configuration described herein, administration of a controlled-release preparation or provision of sustained release of a neuroprotective polypeptide results in a cumulative increase in the concentration of the neuroprotective polypeptide in at least one of cerebrospinal fluid (CSF), the brain, or a combination thereof.
[0275] In any embodiment or configuration described herein, the concentration of neuroprotective polypeptides in CSF is in the range of about 10 to about 400 pg / mL.
[0276] In any embodiment or aspect described herein, the ratio of the concentration of polypeptide in stable CFS to the concentration of polypeptide in stable plasma is in the range of about 0.1% to about 5%.
[0277] In any aspect or embodiment described herein, the exendin-4 analog is represented by chemical formula I or a pharmaceutically acceptable salt thereof: Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala Xaa27 Xaa28 -Z1 (Chemical formula I) (In the formula, Xaa1 is His, Arg, Tyr, Ala, Norval, Val, Norleu, or 4-imidazopropionyl. Xaa2 is Ser, Gly, Ala, or Thr. Xaa3 is Ala, Asp, or Glu. Xaa4 is Ala, Norval, Val, Norleu, or Gly. Xaa5 is Ala or Thr, Xaa6 is Ala, Phe, Tyr, or naphthylalanine. Xaa7 is either Thr or Ser. Xaa8 is Ala, Ser, or Thr. Xaa9 is Ala, Norval, Val, Norleu, Asp, or Glu. Xaa10 is Ala, Leu, Ile, Val, pentylglycine, or Met. Xaa11 is either Ala or Ser. Xaa12 is either Ala or Lys. Xaa13 is Ala or Gln, Xaa14 is Ala, Leu, Ile, pentylglycine, Val, or Met. Xaa15 is either Ala or Glu. Xaa16 is either Ala or Glu. Xaa17 is either Ala or Glu. Xaa19 is either Ala or Val. Xaa20 is Ala or Arg. Xaa21 is Ala, Leu, or Lys-NHε-R, where R is Lys, Arg, or a linear or branched alkanoyl having 1 to 10 carbon atoms. Xaa22 is Ala, Phe, Tyr, or naphthylalanine. Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met. Xaa24 is Ala, Glu, or Asp. Xaa25 is Ala, Trp, Phe, Tyr, or naphthylalanine. Xaa26 is either Ala or Leu. Xaa27 is either Ala or Lys. Xaa28 is either Ala or Asn, and Z1 is -OH, -NH2, Gly-Z2, Gly Gly-Z2, Gly Gly Xaa31-Z2, Gly Gly Xaa31 Ser-Z2, Gly Gly Xaa31 Ser Ser-Z2, Gly Gly Xaa31 Ser Ser Gly-Z2, Gly Gly Xaa31 Ser Ser Gly Ala-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2, or Gly Gly Xaa31 Ser Ser Gly Ala Xaa31, Xaa36, Xaa37, and Xaa38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine, or N-alkylalanine, and Xaa39 is Ser or Tyr (for example, Ser), and Z2 is -OH or -NH2. however, Of Xaa3, Xaa4, Xaa5, Xaa6, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27, and Xaa28, no more than three are Ala, and If Xaa1 is His, Arg, or Tyr, then at least one of Xaa3, Xaa4, and Xaa9 is Ala.
[0278] In any aspect or embodiment described herein, the exendin-4 analog is represented by chemical formula II or a pharmaceutically acceptable salt thereof: Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala X1-Z1 (Chemical formula II) (In the formula, Xaa1 is His, Arg, Tyr, Ala, Norval, Val, Norleu, or 4-imidazopropionyl. Xaa2 is Ser, Gly, Ala, or Thr. Xaa3 is Ala, Asp, or Glu. Xaa4 is Ala, Norval, Val, Norleu, or Gly. Xaa5 is Ala or Thr, Xaa6 is Ala, Phe, Tyr, or naphthylalanine. Xaa7 is either Thr or Ser. Xaa8 is Ala, Ser, or Thr. Xaa9 is Ala, Norval, Val, Norleu, Asp, or Glu. Xaa10 is Ala, Leu, Ile, Val, pentylglycine, or Met. Xaa11 is either Ala or Ser. Xaa12 is either Ala or Lys. Xaa13 is Ala or Gln, Xaa14 is Ala, Leu, Ile, pentylglycine, Val, or Met. Xaa15 is either Ala or Glu. Xaa16 is either Ala or Glu. Xaa17 is either Ala or Glu. Xaa19 is either Ala or Val. Xaa20 is either Ala or Arg. Xaa21 is Ala, Leu, or Lys-NHε-R, where R is Lys, Arg, a linear or branched alkanoyl having 1 to 10 carbon atoms, or a cycloaleyl-alkanoyl. Xaa22 is Phe, Tyr, or naphthylalanine. Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met. Xaa24 is Ala, Glu, or Asp. Xaa25 is Ala, Trp, Phe, Tyr, or naphthylalanine. Xaa26 is either Ala or Leu. X1 is Lys Asn, Asn Lys, Lys-NHε-R Asn, Asn Lys-NHε-R, Lys-NHε-R Ala, Ala Lys-NHε-R, where R is Lys, Arg, a linear or branched alkanoyl having 1 to 10 carbon atoms, or a cycloalkyl alkanoyl. Z1 is -OH, -NH2, Gly-Z2, Gly Gly-Z2, Gly Gly Xaa31-Z2, Gly Gly Xaa31 Ser-Z2, Gly Gly Xaa31 Ser Ser-Z2, Gly Gly Xaa31 Ser Ser Gly-Z2, Gly Gly Xaa31 Ser Ser Gly Ala-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2, or Gly Gly Xaa31 Ser Ser Gly Ala Xaa31, Xaa36, Xaa37, and Xaa38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine, and N-alkylalanine, and Xaa39 is Ser or Tyr, and Z2 is either -OH or -NH2. however, Of Xaa3, Xaa4, Xaa5, Xaa6, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, and Xaa26, no more than three are Ala, and If Xaa1 is His, Arg, Tyr, or 4-imidazopropionyl, then at least one of Xaa3, Xaa4, and Xaa9 is Ala.
[0279] In any aspect or embodiment described herein, the neuroprotective polypeptide is selected from the group consisting of SEQ ID NOs: 1 to 55.
[0280] Each reference cited herein is incorporated herein by reference. Except in the examples and where specifically designated, all numerical values specifying quantities of substances, etc., in this description are understood to be modified by adding the word “approximately”. The upper limits, lower limits, range limits, and ratio limits described herein may be combined independently. Similarly, the ranges and quantities of each element relating to this disclosure may be used together with the ranges or quantities of any other element.
[0281] Those skilled in the art will recognize that many equivalents exist to the specific embodiments and methods described herein, or that such equivalents can be verified using only conventional experimental methods. Such equivalents are intended to be covered by the following claims.
[0282] The detailed examples and embodiments described herein are to be understood as illustrative examples only and are not intended to limit the disclosure. In this regard, various modifications or changes will be suggested to those skilled in the art, and such modifications or changes will be considered to be within the spirit and scope of the application and within the scope of the supplementary claims. For example, the relative amounts of components may be changed, additional components may be added, and / or one or more of the described components may be replaced with similar components in order to optimize the desired effect. Further advantageous features and functionalities relating to the systems, methods, and processes relating to the disclosure will become apparent from the supplementary claims. Furthermore, those skilled in the art will recognize that many equivalents exist to the specific embodiments of the disclosure described herein, or that such equivalents can be verified using only conventional experimental methods. Such equivalents are intended to be included within the scope of the following claims.
[0283] References
[0284] Table 3
Claims
1. Methods for delivering neuroprotective polypeptides to at least a portion of the central nervous system (CNS) of a subject - Patents.com Controlled release preparations or devices for use in And, The method comprises: A therapeutically effective amount of the neuroprotective polypeptide is administered to provide sustained release of the neuroprotective polypeptide. The above Controlled release preparations or The above administering to the subject's systemic circulatory bloodstream with a device, wherein the neuroprotective polypeptide comprises at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog; The neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; The controlled release neuroprotective preparation or sustained release of the neuroprotective polypeptide increases delivery and / or uptake of the neuroprotective polypeptide across the blood-brain barrier (BBB) and into at least a portion of the central nervous system (CNS) of the subject compared to an immediate release preparation of the neuroprotective peptide. Controlled Release Preparations or Devices .
2. 2. The method of claim 1, wherein the controlled release formulation is a sustained release formulation of the neuroprotective polypeptide. Controlled Release Preparations or Devices .
3. The controlled release preparation according to claim 1 or 2 further comprises a biodegradable polymer having a specific viscosity and a coating material to achieve bioavailability and sustained release of an effective amount of the neuroprotective polypeptide over a sufficient period of time. Controlled Release Preparations or Devices .
4. The controlled release neuroprotective preparation comprises: a controlled release microsphere comprising a core comprising said neuroprotective polypeptide and a biodegradable polymer; and a coating layer that coats the core. Controlled Release Preparations or Devices .
5. 3. The method of claim 2, wherein the sustained release preparation comprises a depot preparation for sustained release of the neuroprotective polypeptide. Controlled Release Preparations or Devices .
6. The sustained release preparation comprises a composition for sustained release of the neuroprotective polypeptide. To Described Controlled Release Preparations or Devices .
7. Methods of Treating a Subject Having a Central Nervous System (CNS)-Related Disease or Reducing at Least One Symptom of a CNS-Related Disease in a Subject in Need of Reducing That Symptom Controlled release preparations or devices for use in And, The method comprises: A therapeutically effective amount of a neuroprotective polypeptide is administered to provide sustained release of said neuroprotective polypeptide. The above Controlled release preparations or The above administering to the subject's systemic circulatory bloodstream with a device, wherein the neuroprotective polypeptide comprises at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analog; The neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; The controlled release neuroprotective preparation or sustained release of the neuroprotective polypeptide increases delivery of the neuroprotective polypeptide across the blood-brain barrier (BBB) to at least a portion of the central nervous system (CNS) of the subject compared to an immediate release preparation of the neuroprotective polypeptide. Controlled Release Preparations or Devices .
8. 8. The method of claim 7, wherein the controlled release preparation is a sustained release preparation of the neuroprotective polypeptide. Controlled Release Preparations or Devices .
9. The controlled release preparation according to claim 7 or 8, further comprising a biodegradable polymer having a specific viscosity and a coating material, so that the bioavailability and sustained release of the neuroprotective polypeptide at an effective concentration continues over a period of time. Controlled Release Preparations or Devices .
10. The controlled release neuroprotective preparation comprises: a controlled release microsphere comprising a core comprising said neuroprotective polypeptide and a biodegradable polymer; and a coating layer that coats the core. Controlled Release Preparations or Devices .
11. 9. The method of claim 8, wherein the sustained release preparation comprises a depot preparation for sustained release of the neuroprotective polypeptide. Controlled Release Preparations or Devices .
12. The sustained release preparation of claim 8 comprises a composition for sustained release of the neuroprotective polypeptide. Controlled Release Preparations or Devices .
13. The biodegradable polymer according to any one of claims 3, 4, 9, or 10, wherein the biodegradable polymer is selected from the group consisting of polylactide (PLA), polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), polyorthoester, polyanhydride, polyhydroxybutyric acid, polycaprolactone, and polyalkylcarbonate, a copolymer or a simple mixture of two or more polymers selected from the group of polymers, a copolymer of the polymer and polyethylene glycol (PEG), or a polymer-sugar conjugate formed by coupling a sugar to the polymer or the copolymer. Controlled Release Preparations or Devices .
14. 14. The method of claim 1, wherein administering the controlled release neuroprotective preparation comprises injecting the controlled release neuroprotective preparation into the subject. Controlled Release Preparations or Devices .
15. 15. The method of claim 14, wherein the injection of the controlled release preparation into the subject is a subcutaneous injection. Controlled Release Preparations or Devices .
16. 16. The method of claim 1, wherein the administration of the controlled release preparation is performed about 7 to about 21 days (e.g., about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, or about 21 days) after the preceding administration. Controlled Release Preparations or Devices .
17. The device according to any one of claims 1 to 13, wherein the device provides a sustained release of the controlled release preparation. Controlled Release Preparations or Devices .
18. 18. The device of claim 1, 8, or 17, wherein the device is a pump (e.g., a pump, a minipump, an osmotic pump, an osmotic delivery device, an infusion pump, an intravenous administration device, a peristaltic pump, or a mini infusion pump, etc.). Controlled Release Preparations or Devices .
19. 19. The method of claim 1, 8, 17, or 18, wherein the neuroprotective polypeptide is administered with the device at a rate of about 1 pM / kg / min to about 30 pM / kg / min (e.g., about 3 pM / kg / min to about 17.5 pM / kg / min). Controlled Release Preparations or Devices .
20. 20. The method of claim 1, wherein administration of the neuroprotective polypeptide to the systemic circulation alleviates at least one symptom of at least one CNS-related condition in the subject. Controlled Release Preparations or Devices .
21. 21. The method of claim 20, wherein the CNS-related condition is selected from the group consisting of Parkinson's disease (PD), traumatic brain injury (TBI), multiple sclerosis, drug addiction, alcohol addiction, neurodegenerative conditions, brain inflammation, Alzheimer's disease (AD), multiple system atrophy, Huntington's disease, chronic traumatic encephalopathy (CTE), motor neuron disease (e.g., amyotrophic lateral sclerosis, spinal cord injury, spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)), vascular dementia, dementia with Lewy bodies (DLB), mixed dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, or a combination thereof. Controlled Release Preparations or Devices .
22. by administration of said controlled release preparation, or The above 22. The method of claim 1, wherein the device provides sustained release of the neuroprotective polypeptide, resulting in a steady state concentration of the neuroprotective polypeptide in plasma within the range of about 50 to about 4500 pg / mL. Controlled Release Preparations or Devices .
23. by administration of said controlled release preparation, or The above 23. The method of claim 1, wherein the device provides sustained release of the neuroprotective polypeptide, resulting in a cumulative increase in the concentration of the neuroprotective polypeptide in at least one of the cerebrospinal fluid (CSF), the brain, or a combination thereof. Controlled Release Preparations or Devices .
24. 24. The method of claim 1, wherein the concentration of the neuroprotective polypeptide in the CSF is in the range of about 10 to about 400 pg / mL. Controlled Release Preparations or Devices .
25. 25. The method according to any one of claims 1 to 24, wherein the ratio of the concentration of said polypeptide in CFS at steady state to the concentration of said polypeptide in plasma at steady state is within the range of about 0.1% to about 5%. Controlled Release Preparations or Devices .
26. The exendin-4 analog of any one of claims 1 to 25 is represented by formula I, or a pharma- ceutically acceptable salt thereof. Controlled Release Preparations or Devices : Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25 Xaa26 Xaa27 Xaa28 -Z 1 (Chemical formula I) (In the formula, Xaa1 is His, Arg, Tyr, Ala, Norval, Val, Norleu, or 4-imidazopropionyl; Xaa2 is Ser, Gly, Ala, or Thr; Xaa3 is Ala, Asp, or Glu; Xaa4 is Ala, Norval, Val, Norleu, or Gly; Xaa5 is Ala or Thr; Xaa6 is Ala, Phe, Tyr, or naphthylalanine; Xaa7 is Thr or Ser; Xaa8 is Ala, Ser, or Thr; Xaa9 is Ala, Norval, Val, Norleu, Asp, or Glu; Xaa10 is Ala, Leu, Ile, Val, pentylglycine, or Met; Xaa11 is Ala or Ser; Xaa12 is Ala or Lys; Xaa13 is Ala or Gln, Xaa14 is Ala, Leu, Ile, pentylglycine, Val, or Met; Xaa15 is Ala or Glu, Xaa16 is Ala or Glu, Xaa17 is Ala or Glu, Xaa19 is Ala or Val, Xaa20 is Ala or Arg; Xaa21 is Ala, Leu, or Lys-NHε-R, where R is Lys, Arg, or a linear or branched alkanoyl having 1 to 10 carbon atoms; Xaa22 is Ala, Phe, Tyr, or naphthylalanine; Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met; Xaa24 is Ala, Glu, or Asp; Xaa25 is Ala, Trp, Phe, Tyr, or naphthylalanine; Xaa26 is Ala or Leu; Xaa27 is Ala or Lys; Xaa28 is Ala or Asn, and WITH 1 は、-OH、-NH 2 、Gly-Z 2 、Gly Gly-Z 2 、Gly Gly Xaa31-Z 2 、Gly Gly Xaa31 Ser-Z 2 、Gly Gly Xaa31 Cheese Cheese-Z 2 、Gly Gly Xaa31 Ser Ser Gly-Z 2 、Gly Gly Xaa31 Ser Ser Gly Ala-Z 2 、Gly <h2 style=";text-align:left;direction:ltr">Gly Xaa31 Ser Ser Gly Ala Xaa36-Z<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr"> Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr"> Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr"> 、またはGly Gly Xaa31 Ser Ser Gly <h2 style=";text-align:left;direction:ltr">Ala Xaa36 Xaa37 Xaa38 Xaa39-Z<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr">であり、 Xaa31, Xaa36, Xaa37, and Xaa38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine, or N-alkylalanine; Xaa39 is Ser, or Tyr (e.g., Ser); and Z 2 -OH or -NH 2 and however, Not more than three of Xaa3, Xaa4, Xaa5, Xaa6, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27, and Xaa28 are Ala; and When Xaa1 is His, Arg, or Tyr, then at least one of Xaa3, Xaa4, and Xaa9 is Ala).
27. The exendin-4 analog of any one of claims 1 to 25 is represented by formula II, or a pharma- ceutically acceptable salt thereof. Controlled Release Preparations or Devices : Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25 Xaa26 X 1 -Z 1 (Chemical formula II) (In the formula, Xaa1 is His, Arg, Tyr, Ala, Norval, Val, Norleu, or 4-imidazopropionyl; Xaa2 is Ser, Gly, Ala, or Thr; Xaa3 is Ala, Asp, or Glu; Xaa4 is Ala, Norval, Val, Norleu, or Gly; Xaa5 is Ala or Thr; Xaa6 is Ala, Phe, Tyr, or naphthylalanine; Xaa7 is Thr or Ser; Xaa8 is Ala, Ser, or Thr; Xaa9 is Ala, Norval, Val, Norleu, Asp, or Glu; Xaa10 is Ala, Leu, Ile, Val, pentylglycine, or Met; Xaa11 is Ala or Ser; Xaa12 is Ala or Lys; Xaa13 is Ala or Gln, Xaa14 is Ala, Leu, Ile, pentylglycine, Val, or Met; Xaa15 is Ala or Glu, Xaa16 is Ala or Glu, Xaa17 is Ala or Glu, Xaa19 is Ala or Val, Xaa20 is Ala or Arg, Xaa21 is Ala, Leu, or Lys-NHε-R, where R is Lys, Arg, a linear or branched alkanoyl having 1 to 10 carbon atoms, or a cycloarylene-alkanoyl; Xaa22 is Phe, Tyr, or naphthylalanine; Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met; Xaa24 is Ala, Glu, or Asp; Xaa25 is Ala, Trp, Phe, Tyr, or naphthylalanine; Xaa26 is Ala or Leu; X 1 are Lys Asn, Asn Lys, Lys-NHε-R Asn, Asn Lys-NHε-R, Lys-NHε-R Ala, Ala Lys-NHε-R, where R is Lys, Arg, linear or branched alkanoyl having 1 to 10 carbon atoms, or cycloalkylalkanoyl; WITH 1 は、-OH、-NH 2 、Gly-Z 2 、Gly Gly-Z 2 、Gly Gly Xaa31-Z 2 、Gly Gly Xaa31 Ser-Z 2 、Gly Gly Xaa31 Cheese Cheese-Z 2 、Gly Gly Xaa31 Ser Ser Gly-Z 2 、Gly Gly Xaa31 Ser Ser Gly Ala-Z 2 、Gly <h2 style=";text-align:left;direction:ltr">Gly Xaa31 Ser Ser Gly Ala Xaa36-Z<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr"> Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr"> Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr"> 、またはGly Gly Xaa31 Ser Ser Gly <h2 style=";text-align:left;direction:ltr">Ala Xaa36 Xaa37 Xaa38 Xaa39-Z<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr">であり、 Xaa31, Xaa36, Xaa37, and Xaa38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine, and N-alkylalanine; Xaa39 is Ser or Tyr; and Z 2 is -OH or -NH 2 and however, Not more than three of Xaa3, Xaa4, Xaa5, Xaa6, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, and Xaa26 are Ala; and When Xaa1 is His, Arg, Tyr, or 4-imidazopropionyl, then at least one of Xaa3, Xaa4, and Xaa9 is Ala).
28. The neuroprotective polypeptide according to any one of claims 1 to 25, wherein the neuroprotective polypeptide is selected from the group consisting of SEQ ID NOs: 1 to 55. Controlled Release Preparations or Devices .
